 
 
CONFIDENTIAL  
This material is the property of Cedars -Sinai Medical Center. Do not disclose or use except as authorized 
in writing by [CONTACT_564454].  
 
 
 
IIT2016 -16-POSADAS -TRC105  
A phase 2 study of TRC105 (anti -endoglin antibody) with abiraterone and with enzalutamide  in 
patients progressing on therapy  
 
Principal Investigator :  [INVESTIGATOR_564425] M Posadas, MD FACP  
    Urologic Oncology Program  
    Samuel Oschin Comprehensive Cancer Institute  
    Cedars -Sinai Medical Center  
    [ADDRESS_741347], Los Angeles, CA [ZIP_CODE]  
 
Co-Investigator (s):   
Name  [INVESTIGATOR_31242]/Division  
Robert Figlin, MD FACP  Division of Hematology/Oncology  
Kevin Scher, MD MBA  
David Hoffman, MD  
Leland Green, MD  
Fred Rosenfelt , MD  Tower Hematology/Oncology  
Suwicha Limvorasak, PharmD, BCOP  Investigational Pharmacy  
Mourad Tighiouart, PhD  Biostatistics  
Amy Oppenheim  
Johanna Han  
Veronica Placencio, PhD  Research Coordination  
Nancy Moldawer, MSN RN  Research Nursing  
 
Laboratory -Investigator(s):    
Name  [INVESTIGATOR_31242]/Division  
Neil A. Bhowmick, PhD  
(Scientific Lead)  
Leland Chung, PhD  Division of Hematology/Oncology  
Department of Medicine   
Michael Freeman, PhD  
Beatrice Knudsen, MD -PhD 
Dolores DiVizio, MD -PhD Division of Biological Sciences  
Jie-Fu Chen, MD  
Karen Cavassani, PhD  
Veronica Placencio, PhD   
Elisabeth Hodara  
Shirley Cheng  
Alexander Ureno  
Amy Gomez   
Hsian -Rong Tseng, PhD  [LOCATION_004] Nanosystems Institute  
University of [LOCATION_004], Los Angeles  
 
IND Number:    134672  
IND Holder Name:   [CONTACT_564489] , MD  
Funding Source :   Internal ; Planned STTR application to NCI with Tracon  
Initial version:    Version 1 dated 24 AUG  2017  
Clinical Trials.gov:   Registration (pending)  
    Results Reporting (required)   
NCT No.:    Pending  
 
 
CONFIDENTIAL  
This material is the property of Cedars -Sinai Medical Center. Do not disclose or use except as authorized 
in writing by [CONTACT_564454].  
 
 
 
 
 
Signature [CONTACT_264032], and provides the 
necessary assurances that this trial will be conducted according to all stipulations of the protocol, including 
all statements regarding confidentiality, and according to local legal and regulatory requirements and 
applicable U.S. federal regulations and ICH guidelines.  
 
 
 
Principal Investiga tor (PI) Name:  [INVESTIGATOR_564425] M Posadas, MD FACP  
 
 
 
Signature: __________ __________ _________   Date:  ____________________  
 
 
Biostatistician Name: [CONTACT_564490], PhD  
 
 
 
Signature: _____________________________  Date: ____________________  
 
 
Clinical Reviewer Name:  _____________________________  
 
 
 
Signature: _____________________________  Date: ____________________  
 
 
 
 
IIT201 6-16-POSADAS -TRC105  
 
 TABLE OF CONTENTS  
 
LIST OF ABBREVIATIONS  ................................ ................................ ................................ ........  1 
VERSION HISTORY  ................................ ................................ ................................ .................  2 
STUDY SUMMARY  ................................ ................................ ................................ .................  3 
Primary Objectives  ................................ ................................ ................................ ......................... 3 
Secondary Objectives ................................ ................................ ................................ ...................... 3 
STUDY SCHEMA  ................................ ................................ ................................ .....................  4 
1.0 BACKGROUND AND RATIONALE  ................................ ................................ ...................  5 
1.1 Prostate cancer and androgen receptor (AR) inhibition  ................................ .......................... 5 
1.2 Endoglin (CD105)  ................................ ................................ ................................ .................. 5 
1.3 Endoglin and prostate cancer  ................................ ................................ ................................ 6 
1.4 TRC105  ................................ ................................ ................................ ................................ .8 
1.5 TRC105 and prostate cancer  ................................ ................................ ................................  12 
1.6 Rationale  ................................ ................................ ................................ ............................  13 
2.0 STUDY OBJECTIVES  ................................ ................................ ................................ ..... 14 
2.1 Primary Objectives  ................................ ................................ ................................ .............  14 
2.2 Secondary Objectives ................................ ................................ ................................ ..........  14 
2.3 Exploratory Objectives  ................................ ................................ ................................ ........  14 
3.0 ENDPOINTS  ................................ ................................ ................................ ................  15 
4.0 STUDY DESIGN  ................................ ................................ ................................ ...........  16 
5.0 PATIENT ELIGIBILITY  ................................ ................................ ................................ ... 16 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................  16 
5.2 Exclusion Criteria  ................................ ................................ ................................ ................  16 
6.0 TREATMENT PLAN  ................................ ................................ ................................ ...... 17 
6.1 Washout for AR -targeted agents  ................................ ................................ .........................  17 
6.2 Dosing plan  ................................ ................................ ................................ ........................  17 
6.3 Investigational compound ................................ ................................ ................................ ... 17 
6.4 AR-targeted therapy  ................................ ................................ ................................ ...........  20 
6.5 Toxicities and Dosing Delays/Dose Modifications  ................................ ................................  20 
6.6 Concomitant Medications/Treatments  ................................ ................................ ................  [ADDRESS_741348]  ................................ ................................ .........................  25 
7.1 Tumor Assessment  ................................ ................................ ................................ .............  25 
7.2 Definitions ................................ ................................ ................................ ..........................  25 
7.3 PSA response criteria  ................................ ................................ ................................ ..........  27 
IIT201 6-16-POSADAS -TRC105  
 
 7.4 Safety/tolerability  ................................ ................................ ................................ ..............  27 
8.0 ADVERSE EVENTS  ................................ ................................ ................................ .......  28 
8.1 Risks of participation  ................................ ................................ ................................ ..........  28 
1.2 Adverse Event Monitoring  ................................ ................................ ................................ .. 28 
8.2 Definitions ................................ ................................ ................................ ..........................  28 
8.3 Reporting Requirements for Adverse Events ................................ ................................ ........  29 
8.4 Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................................ ....................  30 
9.0 CORRELATIVES/SPECIAL STUDIES  ................................ ................................ ................  [ADDRESS_741349] (IRB) Approval and Consent  ................................ ....................  35 
11.3 Registration Procedures  ................................ ................................ ................................ .. 35 
11.4 Data Management and Monitoring/Auditing  ................................ ................................ ... [ADDRESS_741350]  
ECOG  Eastern Cooperative Oncology Group  
H&P History & Physical Exam  
HRPP  Human Research Protections Program  
IV (or iv)  Intravenously  
MTD  Maximum Tolerated Dose  
NCI National Cancer Institute  
ORR  Overall Response Rate  
OS Overall Survival  
PBMCs  Peripheral Blood Mononuclear Cells  
PD Progressive Disease  
PFS Progression Free Survival  
p.o. per os/by [CONTACT_1966]/orally  
PR Partial Response  
SAE Serious Adverse Event  
SD Stable Disease  
SGOT  Serum Glutamic Oxaloacetic Transaminase  
SPGT  Serum Glutamic Pyruvic Transaminase  
WBC  White Blood Cells  
  
  
 
  
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   2 
 VERSION HISTORY  
  
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   3 
 STUDY SUMMARY  
Title A prospective  study of TRC105 (anti -endoglin antibody) with abiraterone 
or with enzalutamide  
Protocol Number  IIT2016 -16-POSADAS -TRC105  
Phase  2  
Methodology  Parallel Bayesian  phase 2  
Study Duration  24 months  
Study Center(s)  SOCCI and affiliated practices only  
Objectives  Primary Objectives  
 To measure clinical benefit of TRC105 with enzalutamide or 
with abiraterone) in patients who have demonstrated 
resistance by [CONTACT_564455].  
Secondary Objecti ves  
 Describe the adverse events associated with TRC105 and 
abiraterone or enzalutamide.  
 Measure the impact of the addition of TRC105 to abiraterone 
or enzalutamide on serum PSA concentration.  
 Measure the effect of the addition of TRC105 to abiraterone or 
enzalutamide by [CONTACT_564456] (RECIST, Prostate 
Cancer Working Group 3 ( PCWG3 )[43]) after 2 and 4 months.  
 Measure the proportion of patients who remain progression 
free by [CONTACT_62649]/or radiographic measurement at 2 and 4 
months after the addition of TRC105 to abiraterone or 
enzalutamide  
 
Number of Subjects  40 maximum subjects  (limited by [CONTACT_564457])  
 
Arm A: patients progressing on Abiraterone  by [CONTACT_564458] E: patients progressing on Enzalutamide  by [CONTACT_564459], castration -resistant prostate cancer actively progressing on 
abiraterone or enzalutamide by [CONTACT_564460] o rgan function  
ECOG PS [ADDRESS_741351] (s), Dose, 
Route, Regimen  TRC105 10 mg weekly x4 then 15 mg/kg q2weeks; abiraterone or 
enzalutamide per standard dosing  
Duration of administration  Until radiographic progr ession by [CONTACT_393] 1.1 or PCWG3  criteria  
Reference therapy  N/A 
Statistical Methodology  Bayesian phase 2 per Tighiouart  
 
  
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   4 
 STUDY SCHEMA  
 
  

IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   5 
  
1.0 BACKGROUND AND RATIONALE  
1.1 Prostate cancer and androgen receptor (AR) inhibition  
Prostate cancer (PCa) is the most common, non -cutaneous cancer affecting men in the [LOCATION_002] and 
the second leading cause of cancer death in American males.  For those men who do not have disease 
amenable to means of local control, systemic agents are  employed to control disease in efforts to extend 
life and improve quality.  Androgen deprivation therapy (ADT) has been used as the primary mode of 
systemic treatment given the dependence of this cancer upon AR -signaling rooted in the embryonic origin 
of the genitourinary tract.  While ADT is typi[INVESTIGATOR_564426], most men facing metastatic PCa 
will progress to a state of castration resistance and require additional treatment.  Metastatic, castration -
resistant PCa (mCRPC) is universally rec ognized as a lethal evolution in PCa biology.  While there are a 
number of approaches being explored and approved for men affected by [CONTACT_564461], the use of next -
generation AR -inhibition strategies have been among the most effective and widely used.  Examples o f 
such agents include abiraterone acetate and enzalutamide (see below). While these two FDA -approved 
and commercially available agents are effective in many cases, even those men who benefit initially will 
progress to this form of the disease which is no l onger well controlled by [CONTACT_5640] (or both) of these drugs.  
Typi[INVESTIGATOR_897], this manifests as rising serum prostate specific antigen (PSA) concentrations and eventually by 
[CONTACT_564462].  Given therapeutic alternatives s uch as 
chemotherapy, means of extending the benefit of ADT, generally well tolerated , would represent an 
important advancement in PCa therapy.  
1.2 Endoglin (CD105)  
CD105 (endoglin) is a homodimeric cell membrane glycoprotein that was initially identified as a  human 
leukemia -associated antigen [1] and later also found on endothelial cells [2, 3] . CD105 is a TGF -β and BMP 
co-receptor that is essential for angiogenesis [4, 5]  and CD105 is strongly expressed on the proliferating 
vascular endothelium of solid tumors [3, 6] . All of these properties make CD105 an attractive target for the 
antiangiogenic therapy of can cer [7]. Vascular targeted therapy may more effectively address large 
established tumors than conventional antiangiogenic therapy such as anti -VEGF therapy [8]. In animal 
models, CD105 targeted therapy has demonstrated both vascular t argeting effects and antiangiogenic 
effects by [CONTACT_564463] [3, 9-12]. Therefore, CD105 offers a novel alternative target 
relative to the VEGF inhibitors currently available for antiangiogenesis therapy.  
 
CD105 acts to modulate signaling of multiple kinase receptor complexes of the TG F-β superfamily, 
including TGF -β receptors, bone morphogenic protein (BMP)  and activin receptors [13]. Binding of TGF -β 
to CD105  complexed with  TGF-β receptors results in phosphorylation of SMAD  2/3 proteins that  reinforces 
a quiescent phenotype a nd inhibit s endothelial cell growth. However, activation of CD105 by [CONTACT_564464] 1/5, thereby [CONTACT_564465] -β on endothelium. Not 
surprisingly, prevention of BMP binding to CD105 by [CONTACT_2017]-CD105 antibody acts s ynergistically with TGF -
β to inhibit endothelial cell growth  [14].  
 
CD105 expression is required for endothelial cell proliferation, and CD 105 is upregulated in the setting of 
hypoxia through the induction of hypoxia -inducible factor -1-α (HIF -1-α) [15, 16] . CD105 has also been 
shown to protect hypoxic cells from apoptosis [17]. The expression of CD105 by [CONTACT_564466]. Targeted inactivation (knockout) of murine CD105 results 
in defective vascular development. M ice lacking CD105 die in utero  from defective vascular development 
by [CONTACT_28104] 11 [4].  
 
CD105 is critical for normal human blood vessel development [18]. CD105 haplotype insufficiency causes 
a well -described syndrome known as hereditary hemorrhagic telangiectasia type 1 (HHT -1 or Rendu -Osler -
Weber Syndrome). HHT -1 is a rare autosomal dominant genetic disorder characterized by [CONTACT_564467], buccal, gastrointestinal mucosa and skin microvasculature. 
Angiodysplasia also occurs in vessels from internal organs including the lungs, liver and brain [19]. The 
I I T 2 0 1 6-1 6 -PO S A D A S -T R C 1 0 5  
P r o t o c o l  V e r s i o n  1  d a t e d  2 4 A UG  2 0 1 7   6 
 g e n o t y p e  i s  m a n i f e s t e d  i n  u t e r o ,  b u t  t h e  p h e n o t y p e  d o e s  n o t  b e c om e  a p p a r e n t  u n t i l  m a n y  y e a r s  f o l l o w i n g  
b i r t h .  A f f e c t e d  p a t i e n t s  c omm o n l y  p r e s e n t  w i t h  e p i s t a x i s  i n  t h e  s e c o n d  d e c a d e  o f  l i f e .  T h e  p h e n o t y p e  o f  t h i s  
d i s o r d e r  i s  c h a r a c t e r i z e d  b y  v a s c u l a r  e f f e c t s ,  i n d i c a t i n g  t h e  s p e c i f i c  r o l e  o f  C D 1 0 5  i n  t h e  v a s c u l a t u r e  [ 2 0 ] .   
 
C D 1 0 5  i s  h i g h l y  e x p r e s s e d  o n  t h e  p r o l i f e r a t i n g  e n d o t h e l i a l  c e l l s  o f  t um o r  v e s s e l s  i n c l u d i n g  l u n g ,  b r e a s t ,  
c o l o r e c t a l ,  g a s t r i c ,  l i v e r ,  e n d om e t r i a l ,  r e n a l  c e l l ,  h e a d  a n d  n e c k ,  a n d  o v a r i a n  c a n c e r s .  U n t i l  r e c e n t l y ,  C D 1 0 5  
e x p r e s s i o n  i n  a d u l t s  h a d  b e e n  d em o n s t r a t e d  o n  p r o l i f e r a t i n g  e n d o t h e l i a l  c e l l s  a n d  p r o e r y t h r o b l a s t s ,  a  r e d  
b l o o d  c e l l  p r e c u r s o r  [ 2 1 ] .  C D 1 0 5  e x p r e s s i o n  i s  a  p r o g n o s t i c  f a c t o r  i n  s o l i d  t um o r  p a t i e n t s .  H i g h  m i c r o v e s s e l  
d e n s i t y  o f  C D 1 0 5 -p o s i t i v e  v e s s e l s  h a s  b e e n  c o r r e l a t e d  w i t h  p o o r  p r o g n o s i s  i n  c l i n i c a l  s t u d i e s  o f  b r e a s t  
c a n c e r  [ 2 2 ,  2 3 ] ,  l u n g  c a n c e r  [ 2 4 ] ,  p r o s t a t e  c a n c e r  [ 2 5 ,  2 6 ] ,  c o l o r e c t a l  c a n c e r  [ 2 7 ,  2 8 ] ,  o v a r i a n  c a n c e r  [ 2 9 ,  
3 0 ] ,  g a s t r i c  c a n c e r  [ 3 1 ] ,  e n d om e t r i a l  c a n c e r  [ 3 2 ] ,  a s t r o c y t i c  b r a i n  t um o r s  [ 3 3 ] , h e p a t o c e l l u l a r  c a r c i n om a  [ 3 4 ] ,  
e s o p h a g e a l  a d e n o c a r c i n om a  [ 3 5 ] ,  a n d  h e a d  a n d  n e c k  c a n c e r  [ 3 6 ,  3 7 ] .   
 
P l a sm a  s o l u b l e -C D 1 0 5  ( c l e a v e d  e x t r a c e l l u l a r  d om a i n )  i s  p r o g n o s t i c  i n  r e t r o s p e c t i v e  s t u d i e s  o f  c a n c e r  
p a t i e n t s .  I n  o n e  s t u d y ,  t h e  m e a n  p l a sm a  C D 1 0 5  c o n c e n t r a t i o n  i n  7 6  p a t i e n t s  w i t h  c o l o r e c t a l  c a n c e r  w a s  4 -
f o l d  h i g h e r  t h a n  t h e  m e a n  v a l u e  i n  4 0  h e a l t h y  s u b j e c t s  w i t h o u t  c a n c e r  [ 2 8 ] .  I n  t h e  s t u d y ,  a  p o s i t i v e  c o r r e l a t i o n  
w a s  o b s e r v e d  b e t w e e n  p l a sm a  s o l u b l e -C D 1 0 5  c o n c e n t r a t i o n  a n d  s t a g e  o f  d i s e a s e .   
 
Im p o r t a n t l y ,  C D 1 0 5  e x p r e s s i o n  i s  u p  r e g u l a t e d  i n  t um o r  e n d o t h e l i a l  c e l l s  f o l l o w i n g  i n h i b i t i o n  o f  t h e  V EG F  
p a t h w a y .  C D 1 0 5  e x p r e s s i o n  i n c r e a s e d  m o r e  t h a n  2 -f o l d  i n  h um a n  p a n c r e a t i c  c a n c e r s  g r o w n  i n  m i c e  t r e a t e d  
w i t h  a n  a n t i b o d y  t h a t  b i n d s  V EG F  [ 3 8 ].  S im i l a r l y ,  t r e a tm e n t  o f  h um a n  b l a d d e r  c a n c e r s  g r o w n  i n  m i c e  w i t h  
a n  a n t i b o d y  t h a t  b l o c k s  a c t i v a t i o n  o f  t h e  V EG F  r e c e p t o r  i n c r e a s e d  C D 1 0 5  e x p r e s s i o n  w i t h i n  t h e  c o r e  t um o r  
v a s c u l a t u r e  [ 3 9 ] .  T R C 1 0 5  i s  a  n o v e l  I gG 1  t h a t  b i n d s  C D 1 0 5  w i t h  h i g h  a v i d i t y  a n d  c om p e t i t i v e l y  i n h i b i t s  BM P  
b i n d i n g  t o  C D 1 0 5 .  R e c e n t  s t u d i e s  a t  D u k e  U n i v e r s i t y  e x p l o r e d  t h e  i n  v i t r o  e f f e c t s  o f  d u a l  a n g i o g e n e s i s  
i n h i b i t i o n  u s i n g  b e v a c i z um a b  a n d  T R C 1 0 5  i n  h um a n  um b i l i c a l  v e i n  e n d o t h e l i a l  c e l l s  ( H U V E C ) .  C om b i n a t i o n  
t h e r a p y  w a s  f o u n d  t o  b e  m o r e  p o t e n t  i n  d e c r e a s i n g  H U V E C  p r o l i f e r a t i o n ,  m i g r a t i o n ,  a n d  t u b u l a r  n e t w o r k  
f o rm a t i o n  t h a n  b e v a c i z um a b  o r  T R C 1 0 5  t r e a tm e n t  a l o n e  [ 4 0 ] .   F u r t h e rm o r e ,  T R C 1 0 5  i n d u c e d  a p o p t o s i s  i n  
H U V E C ,  w h i l e  p r om o t i n g  SM A D 2 / 3  p h o s p h o r y l a t i o n  a n d  i n h i b i t i n g  SM A D 1 / 5 / 8  s i g n a l i n g ,  c o n f i rm i n g  i t s  a n t i -
a n g i o g e n i c  p r o p e r t i e s .  F i n a l l y ,  a n t i b o d y  t o  m o u s e  C D 1 0 5  p o t e n t i a t e s  t h e  a c t i v i t y  o f  m u l t i t a r g e t e d  k i n a s e  
i n h i b i t i o n  t h a t  t a r g e t s  t h e  V EG F R -2 ,  i n  
m o u s e  b e a r i n g  c a n c e r  g r a f t s .   
1 . 3  E n d o g l i n  a n d  p r o s t a t e  
c a n c e r  
T h e  B h o wm i c k  l a b  h a s f o u n d  t h a t  
C D 1 0 5  i s  e x p r e s s e d  i n  b o t h  p r o s t a t e  
c a n c e r  e p i t h e l i a   a n d   a s s o c i a t e d  
f i b r o b l a s t s .   F u r t h e rm o r e ,  C D 1 0 5  
e x p r e s s i o n  o n  p r o s t a t i c  e p i t h e l i a  a n d  
a s s o c i a t e d  f i b r o b l a s t s  c o n t r i b u t e s t o  
c a s t r a t e  r e s i s t a n c e .  A n a l y s i s  o f  C D 1 0 5  
e x p r e s s i o n  b y  imm u n o h i s t o c h em i s t r y  
o n  a  t um o r  a r r a y  s h o w e d  t h a t  i n  b e n i g n  
p r o s t a t e  t i s s u e ,  C D 1 0 5  i s  r e s t r i c t e d   
t o  b l o o d  v e s s e l s  ( F i g u r e  1 ) .  I n  c o n t r a s t ,  
e n d o t h e l i a l  c e l l s ,  e p i t h e l i a l  c a n c e r  c e l l s ,  
a n d  s t r om a l  f i b r o b l a s t s  o f  P C a  t i s s u e s  
e x p r e s s e d  C D 1 0 5 .  I n  a d d i t i o n ,  p a t i e n t  
d e r i v e d  t i s s u e s ,  i n c l u d i n g  n e o p l a s t i c  
c e l l s  a n d  a s s o c i a t e d  f i b r o b l a s t s ,  w e r e  
g r a f t e d  i n t o  t h e  s u b -r e n a l  c a p s u l e s  i n  
m i c e  t o  d e v e l o p  p a t i e n t  d e r i v e d  
x e n o g r a f t  ( P D X )  m o d e l s .  A  s u b s e t  o f   
F i g u r e  1.   C D 1 0 5  i s  e x p r e s s e d  i n  p r o s t a t e  t i s s u e .  
Imm u n o h i s t o c h em i c a l  s t a i n i n g  f o r  C D 1 0 5  s t a i n i n g  ( b r o w n )  w a s  
c o u n t e r s t a i n e d  w i t h  h em a t o x y l i n  f o r  t h e  i n d i c a t e d  t i s s u e  
s p e c im e n s .  A .  R e p r e s e n t a t i v e  t i s s u e  s e c t i o n s  f r om  a  t um o r  
m i c r o a r r a y  a r e  s h o w n  ( n  =  4 8 ) .  A r r o w h e a d s  i n d i c a t e  p o s i t i v e  
b l o o d  v e s s e l  s t a i n i n g  a n d  a r r o w s  i n d i c a t e  p o s i t i v e  s t r om a l  c e l l  
s t a i n i n g .  B .  P r o s t a t e  c a n c e r  p a t i e n t  d e r i v e d  x e n o g r a f t  ( P D X )  
t i s s u e  s t a i n i n g  f o r  C D 1 0 5  i s  s h o w n  o n  t h e  i n d i c a t e d  s p e c im e n s  
f o r  m i c e  g i v e n  v e h i c l e  c o n t r o l  o r  e n z a l u t am i d e  t r e a tm e n t . F i g u r e  1 .  C D 1 0 5  i s  e x p r e s s e d  i n  t h e  p r o s t a t e  
E n z a l u t am i d e  +  V e h i c l e  C o n t r o l  C D 1 0 5  A  
B  
Imm u n o h i s t o c h em i c a l  s t a i n i n g  f o r  C D 1 0 5  s t a i n i n g  ( b r o w n )  w a s  c o u n t e r s t a i n e d  w i t h  
h em a t o x y l i n  f o r  t h e  i n d i c a t e d  t i s s u e  s p e c im e n s .  A .  R e p r e s e n t a t i v e  t i s s u e  s e c t i o n s  f r om  a  
t um o r  m i c r o a r r a y  a r e  s h o w n  ( n  =  4 8 ) .  A r r o w h e a d s  i n d i c a t e  p o s i t i v e  b l o o d  v e s s e l  s t a i n i n g  
a n d  a r r o w s  i n d i c a t e  p o s i t i v e  s t r om a l  c e l l  s t a i n i n g .  B .  P r o s t a t e  c a n c e r  p a t i e n t  d e r i v e d  
x e n o g r a f t  ( P D X )  t i s s u e  s t a i n i n g  f o r  C D 1 0 5  i s  s h o w n  o n  t h e  i n d i c a t e d  s p e c im e n s  f o r  m i c e  
g i v e n  v e h i c l e  c o n t r o l  o r  e n z a l u t am i d e  t r e a tm e n t .   V e h i c l e  C o n t r o l  
 
I I T 2 0 1 6-1 6 -PO S A D A S -T R C 1 0 5  
P r o t o c o l  V e r s i o n  1  d a t e d  2 4 A UG  2 0 1 7   7 
 P D X  m i c e  r e c e i v e d  E n z a l u t am i d e  t r e a tm e n t . 
C D 1 0 5  e x p r e s s i o n  w a s  s h o w n  t o  b e  e l e v a t e d  
f o l l o w i n g  e n z a l u t am i d e  t r e a tm e n t  c om p a r e d  t o  
c o n t r o l  m i c e .   
 
I n t e r e s t i n g l y ,  a n t a g o n i z i n g  C D 1 0 5  h a s  n o  
s t a t i s t i c a l l y  s i g n i f i c a n t  e f f e c t  o n  p r o s t a t e  
c a n c e r  c e l l  l i n e s  ( P C 3 ,  2 2 R v 1 ,  L N C a P ,  C 4 2 B )  
a n d  m i n im a l  e f f e c t  o n  p r im a r y  p r o s t a t i c  
f i b r o b l a s t s  i n  n o rm o x i c  c o n d i t i o n s  i n  v i t r o  ( 2 1%  
O2). T h e  t r e a tm e n t  o f  T R C 1 0 5  t o  t h e s e  c e l l s  
d i d  n o t  a p p r e c i a b l y  c h a n g e  t h e  c e l l  s u r f a c e  
e x p r e s s i o n  o f  C D 1 0 5 ,  a s  d e t e rm i n e d  b y  f l o w  
s o r t i n g  i n  n o rm o x i c  c o n d i t i o n s .  I n  c o n t r a s t ,  
u n d e r  h y p o x i c  c o n d i t i o n s  ( 2%  O 2) ,  m im i c k i n g  
t h e  o x y g e n  c o n c e n t r a t i o n  f o u n d  i n  s o l i d  
t um o r s ,  C D 1 0 5  w a s  e l e v a t e d  d r am a t i c a l l y  i n  
b o t h  2 2 R v 1  e p i t h e l i a  a n d  p r im a r y  p r o s t a t e  
f i b r o b l a s t s  (F i g u r e   2 ). F u r t h e rm o r e ,  
e n z a l u t am i d e  t r e a tm e n t  i n  h y p o x i a  l e d  t o  
e l e v a t e d  C D 1 0 5  l e v e l s ,  s im i l a r  t o  t h o s e  
o b s e r v e d  i n  m i c e .  C om b i n a t i o n  t r e a tm e n t  o f  
T R C 1 0 5  w i t h  e n z a l u t am i d e  de c r e a s e d  t h e s e  
e l e v a t e d  l e v e l s . I t  h a s  b e e n  s h o w n  t h a t  h um a n   
e p i t h e l i a l  2 2 R v 1  c e l l s  x e n o g r a f t e d  i n  i s o l a t i o n  
o f  t h e i r  s t r om a l  C A F  c o u n t e r p a r t  a r e  s e n s i t i v e  
t o  e n z a l u t am i d e  t h e r a p y .   
 
   
F i g u r e  2 .  C D 1 0 5  e x p r e s s i o n  i s  e l e v a t e d  d u e  t o  
e n z a l u t am i d e  t r e a tm e n t  u n d e r  h y p o x i c  c o n d i t i o n s  t h a t  
m im i c  p h y s i o l o g i c  c o n d i t i o n s .   H um a n  p r o s t a t e  c a n c e r  
( P C a )  e p i t h e l i a l  c e l l s  ( r e d  b o x e s )  w e r e  g r o w n  i n  3 D  c o -
c u l t u r e s  w i t h  m o u s e  f i b r o b l a s t s  ( b l u e  b o x e s )  u n d e r  h y p o x i a  
( 2%  O 2 )  w i t h  t h e  i n d i c a t e d  t r e a tm e n t s .  A f t e r  7 2  h o u r s ,  t h e  
c e l l s  w e r e  d i s s o c i a t e d  a n d  a s s e s s e d  b y  F A C S  f o r  C D 1 0 5  
e x p r e s s i o n  a s  s h o w n .  A n t a g o n i z i n g  C D 1 0 5  b y  e i t h e r  M 1 0 4 3  
o r  T R C 1 0 5  d o w n  r e g u l a t e d  e n z a l u t am i d e -i n d u c e d  C D 1 0 5  
c e l l  s u r f a c e  e x p r e s s i o n  i n  b o t h  m o u s e  p r o s t a t i c  f i b r o b l a s t s  
a n d  h um a n  p r o s t a t e  c a n c e r  e p i t h e l i a .  
 
F i g u r e  3 .  H um a n  p r o s t a t e  c a n c e r  CW 2 2 R v 1  e p i t h e l i a l  c e l l s  w e r e  o r t h o t o p i c a l l y  x e n o g r a f t e d  w i t h  c a r c i n om a  
a s s o c i a t e d  f i b r o b l a s t s .  A.  R e l a t i v e  t um o r  v o l um e  ( n o rm a l i z e d  t o  c a s t r a t e d  ( C x )  P B S  c o n t r o l  t um o r s )  i s  
p l o t t e d  f o r  t h e  i n d i c a t e d  m o u s e  t r e a tm e n t  g r o u p s .  B.  G r o s s  p i c t u r e s  o f  t h e  o r t h o t o p i c  p r o s t a t e  t um o r s  w i t h i n  
t h e  p r o s t a t e  a r e  s h o w n  f o r  t h e  i n d i c a t e d  m o u s e  t r e a t m e n t  g r o u p s .  C.  Imm u n o h i s t o c h em i c a l  s t a i n i n g  i s  
s h o w n  f o r  t h e  f o r  t h e  i n d i c a t e d  m o u s e  t r e a tm e n t  g r o u p s .  H & E  s t a i n i n g  i n  t h e  t o p  p a n e l s  s h o w s  t h e  
m o r p h o l o g y  o f  t h e  p r o s t a t e  t um o r s .  P h o s p h o r y l a t e d  h i s t o n e -H 3  ( P H -H 3 )  i n d i c a t e  c e l l s  u n d e r g o i n g  m i t o s i s ,  
c h r om a g r a n i n  A  ( C h r om A )  i n d i c a t e  n e u r o e n d o c r i n e  d i f f e r e n t i a t i o n ,  a n d  T U N E L  i s  a n  a p o p t o t i c  c e l l  m a r k e r .  
A l l  t i s s u e s  w e r e  c o u n t e r s t a i n e d  w i t h  h em a t o x y l i n  ( b l u e ) .   F i g u r e  3 .  T R C 1 0 5  s e n s i t i z e  C R P C  t o  e n z a l u t am i d e  
C  
H um a n  p r o s t a t e  c a n c e r  CW 2 2 R v 1  e p i t h e l i a l  c e l l s  w e r e  o r t h o t o p i c a l l y  x e n o g r a f t e d  w i t h  
c a r c i n om a  a s s o c i a t e d  f i b r o b l a s t s .  A .  R e l a t i v e  t um o r  v o l um e  ( n o rm a l i z e d  t o  c a s t r a t e d  
(C x )  P B S  c o n t r o l  t um o r s )  i s  p l o t t e d  f o r  t h e  i n d i c a t e d  m o u s e  t r e a tm e n t  g r o u p s .  B .  G r o s s  
p i c t u r e s  o f  t h e  o r t h o t o p i c  p r o s t a t e  t um o r s  w i t h i n  t h e  p r o s t a t e  a r e  s h o w n  f o r  t h e  i n d i c a t e d  
m o u s e  t r e a tm e n t  g r o u p s .  C .  Imm u n o h i s t o c h em i c a l  s t a i n i n g  i s  s h o w n  f o r  t h e  f o r  t h e  
i n d i c a t e d  m o u s e  t r e a tm e n t  g r o u p s .  H & E  s t a i n i n g  i n  t h e  t o p  p a n e l s  s h o w s  t h e  
m o r p h o l o g y  o f  t h e  p r o s t a t e  t um o r s .  P h o s p h o r y l a t e d  h i s t o n e - H 3  ( P H - H 3 )  ( b r o w n )  i n  t h e  
s e c o n d  r o w  i n d i c a t e  c e l l s  u n d e r g o i n g  m i t o s i s ,  c h r om a g r a n i n  A  ( C h r om A )  ( b r o w n )  i n  t h e  
t h i r d  r o w  i n d i c a t e  n e u r o e n d o c r i n e  d i f f e r e n t i a t i o n ,  a n d  T e rm i n a l  d e o x y n u c l e o t i d y l  
t r a n s f e r a s e  d U T P  n e c k  e n d  l a b e l i n g  ( T U N E L )  ( b r o w n )  i s  a n  a p o p t o t i c  c e l l  m a r k e r .  A l l  
t i s s u e s  w e r e  c o u n t e r s t a i n e d  w i t h  h em a t o x y l i n  ( b l u e ) .   
 
I I T 2 0 1 6-1 6 -PO S A D A S -T R C 1 0 5  
P r o t o c o l  V e r s i o n  1  d a t e d  2 4 A UG  2 0 1 7   8 
 N o t a b l y ,  t h e  B h o wm i c k  l a b  h a s  s h o w n  t h a t  x e n o g r a f t s  u s i n g  2 2 R v 1  c e l l s  c om b i n e d  w i t h  h um a n  c a n c e r  
a s s o c i a t e d  f i b r o b l a s t s  ( C A F s )  d e r i v e d  f r om  p a t i e n t  b i o p s i e s  l e d  t o  r e s i s t a n c e  o f  2 2 R v 1  c e l l s  f o l l o w i n g  
c a s t r a t i o n  o r  e n z a l u t am i d e  t r e a tm e n t .  T o  f u r t h e r  t e s t  T R C 1 0 5  i n  t h e  c o n t e x t  o f  a n  i n  v i v o  s y s t em  t h a t  m im i c s  
t h e  p a t i e n t  p o p u l a t i o n  p r o p o s e d  i n  t h i s  c l i n i c a l  t r i a l ,  h um a n  e p i t h e l i a l  2 2 R v 1  c e l l s  a n d  C A F s  w e r e  
o r t h o t o p i c a l l y  x e n o g r a f t e d  a n d  t r e a t e d  w i t h  c om b i n a t i o n s  o f  c a s t r a t i o n  ( s im i l a r  t o  ab i r a t e r o n e  t r e a tm e n t ) ,  
w i t h  o r  w i t h o u t  en z a l u t am i d e ,  a n d  w i t h  o r  w i t h o u t  T R C 1 0 5 . Adm i n i s t e r i n g  T R C 1 0 5  i n  t h e  c o n t e x t  o f  
c a s t r a t i o n  o r  c a s t r a t i o n  p l u s  e n z a l u t am i d e  r e s u l t e d  i n  a  s i g n i f i c a n t  d e c r e a s e  i n  t um o r  s i z e  c om p a r e d  t o  
c a s t r a t i o n  o r  c a s t r a t i o n  p l u s  e n z a l u t am i d e  (F i g u r e  3 ).  T h u s ,  b l o c k a d e  o f  C D 1 0 5  i n  f i b r o b l a s t s  a n d  c a n c e r  
c e l l s  s e n s i t i z e s  t h e  P C a  t o  A D T .   
 
V a s c u l a r  a n t a g o n i s t s  h a v e  f a i l e d  
i n  v a r i o u s  s t a g e s  o f  P C a  t h e r a p y  
i n  p a t i e n t s .  T o  d e t e rm i n e  t h e  
m e c h a n i sm  o f  a c t i o n  f o r  T R C 1 0 5  
t o  b e  e f f e c t i v e ,  w e  a n a l y z e d  t h e  
r e s u l t i n g  2 2 R v 1 / f i b r o b l a s t  
x e n o g r a f t  t i s s u e s .  T h e y  w e r e  
f o u n d  t o  e x p r e s s  e l e v a t e d  l e v e l s  
o f  t h e  n e u r o e n d o c r i n e  
d i f f e r e n t i a t i o n  m a r k e r  
c h r om a g r a n i n  A  w h e n  t r e a t e d  
w i t h  c a s t r a t i o n  o r  c a s t r a t i o n  p l u s  
en z a l u t am i d e ,  w h i c h  h a s  b e e n  
s h o w n  t o  p r om o t e  c a n c e r  s t em  
c e l l  s u r v i v a l .  H o w e v e r ,  t h e  
a d d i t i o n   o f   T R C 1 0 5  w i t h  
c a s t r a t i o n  p l u s  en z a l u t am i d e  
d e c r e a s e d  t h i s  e l e v a t i o n  o f  
n e u r o e n d o c r i n e   d i f f e r e n t i a t i o n  
( t um o r s  w i t h  T R C 1 0 5  p l u s  
c a s t r a t i o n  w e r e  t o o  sm a l l  t o  
p r o p e r l y   e v a l u a t e   b y  
imm u n o h i s t o c h em i s t r y ) .  T h i s  
s u g g e s t s  t h a t  T R C 1 0 5  p r om o t e d  
t h e  d i f f e r e n t i a t i o n  o f  t h e  P C a  
e p i t h e l i a ,   w h i c h   m a k e s   i t  
s e n s i t i v e  t o  a n d r o g e n  d e p r i v a t i o n  
t h e r a p i e s  i n s t e a d  o f  d e v e l o p i n g  
c a s t r a t e   r e s i s t a n c e   a n d  
r e c u r r e n c e .  T o  f u r t h e r  a d d r e s s  
t h i s  m e c h a n i sm ,  w e  h a v e  s h o w n  
t h a t   T R C 1 0 5  t r e a tm e n t  
d e c r e a s e d  t h e  e x p r e s s i o n  o f  
a n d r o g e n   r e c e p t o r   s p l i c e  
v a r i a n t s  ( A R -v 7  i n  f i b r o b l a s t s  a n d  
A R -v 5 6 7  i n  e p i t h e l i a )  i n d u c e d  b y  
en z a l u t am i d e  (F i g u r e  4 ). 
1 . 4  T R C 1 0 5  
1 . 4 . 1  B a c k g r o u n d  
T R C 1 0 5  i s  a  g e n e t i c a l l y  e n g i n e e r e d  h um a n /m u r i n e  c h im e r i c  m o n o c l o n a l  a n t i b o d y  d i r e c t e d  a g a i n s t  h um a n  
C D 1 0 5  d e v e l o p e d  b y  T r a c o n  p h a rm a c e u t i c a l s .  T h e  a n t i b o d y  i s  a n  I gG 1  k a p p a  imm u n o g l o b u l i n  c o n t a i n i n g  
m u r i n e  v a r i a b l e  r e g i o n  s e q u e n c e s  a n d  h um a n  c o n s t a n t  r e g i o n  s e q u e n c e s  [ 4 1 ] .  T R C 1 0 5  h a s  a n  
a p p r o x im a t e  m o l e c u l a r  w e i g h t  o f  1 4 8  k D a .  T R C 1 0 5  h a s  a  b i n d i n g  a v i d i t y  f o r  h um a n  C D 1 0 5  o f  a p p r o x im a t e l y  
5  pM .  T R C 1 0 5  i s  f o rm u l a t e d  i n  a  h i s t i d i n e  b u f f e r a t  a  c o n c e n t r a t i o n  o f  25  m g /m L .    
F i g u r e  4 .  A n d r o g e n  r e c e p t o r  v a r i a n t s  u p r e g u l a t e d  b y  a n d r o g e n  
d e p r i v a t i o n  t h e r a p y  a r e  i n h i b i t e d  b y  T R C 1 0 5 .  A.  A  d i a g r am  o f  t h e  
v a r i o u s  A R  s p l i c e  v a r i a n t s  i s  s h o w n .  B.  H um a n  p r o s t a t e  e p i t h e l i a l  c e l l  
l i n e  CW 2 2 R v 1  o r  p r im a r y  p r o s t a t e  c a r c i n om a  a s s o c i a t e d  f i b r o b l a s t s  
( C A F )  w e r e  t r e a t e d  w i t h  c o n t r o l  ( C t r l )  o r  e n z a l u t am i d e  ( E n z a )  a n d  
c h e c k e d  f o r  m R N A  e x p r e s s i o n  o f  v a r i o u s  A R  s p l i c e  v a r i a n t s  a s  
i n d i c a t e d  a n d  G A P D H  c o n t r o l  e x p r e s s i o n .  C.  CW 2 2 R v 1  a n d  C A F  c e l l s  
w e r e  t r e a t e d  w i t h  c o n t r o l  o r  T R C 1 0 5  ( T R C )  a n d  a s s e s s e d  f o r  t h e  
i n d i c a t e d  m R N A  e x p r e s s i o n  o f  A R  s p l i c e  v a r i a n t s  a n d  N o t c h  
d o w n s t r e am  s i g n a l i n g  p r o t e i n s  ( H e y 1  a n d  R N P C 1 )  t h o u g h t  t o  b e  
r e s p o n s i b l e  f o r  t h e  c h a n g e s  A R  v a r i a n t  e x p r e s s i o n .  R e d  a r r o w s  
i n d i c a t e  t h e  l o s s  o f  A R  v a r i a n t s  w i t h  T R C 1 0 5  t r e a tm e n t .  F i g u r e  4 .  A n d r o g e n  r e c e p t o r  v a r i a n t s  u p r e g u l a t e d  b y  a n d r o g e n  d e p r i v a t i o n  
t h e r a p y  a r e  i n h i b i t e d  b y  T R C 1 0 5  
A  
B  
2 2 R v 1   C A F 1  C  
A.  A  d i a g r am  o f  t h e  v a r i o u s  A R  s p l i c e  v a r i a n t s  i s  s h o w n .  B .  H um a n  p r o s t a t e  e p i t h e l i a l  
c e l l  l i n e  CW 2 2 R v 1  o r  p r im a r y  p r o s t a t e  c a r c i n om a  a s s o c i a t e d  f i b r o b l a s t s  ( C A F )  w e r e  
t r e a t e d  w i t h  c o n t r o l  ( C t r l )  o r  e n z a l u t am i d e  ( E n z a )  a n d  c h e c k e d  f o r  m R N A  e x p r e s s i o n  
o f  v a r i o u s  A R  s p l i c e  v a r i a n t s  a s  i n d i c a t e d  a n d  G A P D H  c o n t r o l  e x p r e s s i o n .  C .  
CW 2 2 R v 1  a n d  C A F  c e l l s  w e r e  t r e a t e d  w i t h  c o n t r o l  o r  T R C 1 0 5  ( T R C )  a n d  a s s e s s e d  f o r  
t h e  i n d i c a t e d  m R N A  e x p r e s s i o n  o f  A R  s p l i c e  v a r i a n t s  a n d  N o t c h  d o w n s t r e am  s i g n a l i n g  
p r o t e i n s  ( H e y 1  a n d  R N P C 1 )  t h o u g h t  t o  b e  r e s p o n s i b l e  f o r  t h e  c h a n g e s  A R  v a r i a n t  
e x p r e s s i o n .  R e d  a r r o w s  i n d i c a t e  t h e  l o s s  o f  A R  v a r i a n t s  w i t h  T R C 1 0 5  t r e a tm e n t .  
 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   9 
  
SN6j, the murine parent antibody of TRC105, binds to human umbilical vein endothelial cells (HUVECs) 
with nearly identical avidity as TRC105. SN6j has been shown to bind the tumor vasculature of malignant 
tissues includi ng prostate, breast, colon, rectum, kidney and lung cancers and to inhibit the growth of tumor 
xenografts [10]. Reactivity with tumor tissues is most dense  on the tumor endothelium, as CD105 is not 
generally expressed on epi[INVESTIGATOR_28056] [9]. TRC105 induces ADCC on proliferating HUVECs at low 
concentrations  and induces apoptosis and growth inhibition at higher concentrations.  
1.4.[ADDRESS_741352] been completed. An open -label, phase 1,  multicenter 
study of TRC105 (Study 105ST101) is complete. Fifty patients were treated until  disease progression with 
TRC105 at 0.01 -15 mg/kg/q2wk or 10 -15 mg/kg/wk. Completed studies include a phase 1 study of TRC105 
monotherapy in prostate cancer (Karzai, 2015), phase 1b study of TRC105 in combination with 
bevacizumab, phase 2 studies of TRC105 monotherapy in liver cancer and ovarian cancer, and in 
combination with bevacizumab in glioblastoma multiforme (2 studies) and renal cell carcinoma. Ongoing 
studies  include  phase 1b /2 studies of TRC105 in combination with  sorafenib , a phase 2 stud y of TRC105 
in combination with  axitinib in renal cell carcinoma , and a phase 2 study of TRC105 in combination with 
pazopanib in soft tissue sarcoma .  
 
In Study 105ST101, intensive PK was collected following TRC105 administration on Cycle 1 Day 1 and 
Cycle 2 Day 15 and pre -dose concentrations were taken before dosing in subsequent cycles.  Volume of 
distribution was similar to plasma volume, which was consistent with preclinical toxi cokinetics and would 
be expected for an antibody administered intravenously.   AUC increased supra -proportionally with dose 
whereas the C max appeared to be dose proportional .  TRC105 clearance was consistent with target 
mediated disposition and decreased cl earance at higher doses suggests beginning of target saturation. 
Serum concentrations were achieved continuously at doses of 15 mg/kg every 2 weeks (in most but not all 
patients) and 10 mg/kg weekly (in all patients), and TRC105 accumulated at a dose of 15  mg/kg weekly 
(Figure 5 ).  Importantly, weekly dosing with 10 mg/kg produced continuous TRC105 serum concentrations 
above the target concentration of 25 μg/mL shown to produce maximum inhibition of HUVEC activation in 
vitro (i.e., maximal inhibition of SMA D1 phosphorylation in response to BMP binding ) (Figure 5 ). 
 
 
Figure 5. Single -dose and multiple dose pharmacokinetic data from Study 105ST101  
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   10 
  
In Study 105ST101, serum samples for evaluation of TRC105 immunogenicity, including HAMA and HACA, 
were collected pre -dose on day 1 of each 28 -day cycle, at the end of study,  and then at 4 and 12 weeks 
after the end of study visit.  
 
HAMA and HACA data are available from the phase 1 monotherapy TRC105 trial. Neither  HAMA nor HACA 
were detected in patients tre ated with CHO -produced TRC105, which has been used in all trials since 2007 
and will be used in  this study.  
 
Further studies of a hybrid dosing scheme by [CONTACT_564468]105 is given weekly at 10 mg/kg for four doses 
and then every two weeks at 15 mg/kg indicated  the dose and schedule were tolerable and produced 
continuous TRC105 serum levels above target concentrations in all patients.  This hybrid dosing scheme 
has the advantage of allowing every two week dosing after the initial month of treatment, which improv es 
patient convenience . 
 
A total of 50 patients were treated on Study 105ST101 with escalating doses of TRC105 at 0.01,  0.03, 0.1, 
0.3, 1, 3, 10 and 15 mg/kg every two weeks and then 10 and 15 mg/kg weekly. Dose  escalation proceeded 
stepwise until the top dose was reached. The maximum tolerated dose was  exceeded at 15 mg/kg weekly 
and the recommended phase 2 dose of TRC105 was therefore  determined to be 10 mg/kg weekly  or 15 
mg/kg every two weeks . Three of 4 patients at 15 mg/kg weekly developed grade 3  hypoproliferative anemia 
(without leucopenia or thrombocytopenia) in cycle 2, and one of the  three progressed to grade [ADDRESS_741353] common advers e events, were usually with the initial  TRC105 dose 
and included one or more of the following signs or symptoms: rigors,  bronchospasm, urticaria, hypertension, 
hypotension, tachycardia or bradycardia. Infusion  reactions were initially reported at 1 mg/kg e very 2 weeks 
for patients receiving TRC105  produced in NS0 cells without premedication. TRC105 produced in CHO 
cells was known to  more potently engage ADCC in vitro than TRC105 produced in NS0 cells. Because of 
this, the  initial dose level for patients rec eiving CHO -produced TRC105 was de -escalated to 0.3 mg/kg.  
Despi[INVESTIGATOR_28057] -escalation, the first two patients at 0.3 mg/kg treated with CHO -produced  TRC105 
experienced grade [ADDRESS_741354] dose in the absence of  premedicatio n. 
The protocol was therefore amended to require a dexamethasone -based  premedication regimen and 
extend the initial infusion duration from 1 to 4 hours.  
 
The amendment mandating premedication and extended initial infusion duration successfully  reduced the 
frequency and severity of infusion reactions and allowed dose escalation to continue.  One additional patient 
who received CHO -produced TRC105 at 1 mg/kg developed a grade [ADDRESS_741355] dose 
given over 2 hours. This patient had experien ced a grade 2  infusion reaction when the dose was 
administered over 4 hours. In all three patients with grade 3  infusion reactions, TRC105 was not detectable 
in serum at the time of dosing, which allowed de novo binding of TRC105 to CD105 expressing endoth elium 
within the vasculature. Grade 3  infusion reactions were not observed in patients dosed at 10 or 15 mg/kg 
who maintained  TRC105 serum levels known to saturate CD105 binding sites for the full dosing interval. At  
dose levels where continuous TRC105 serum levels were achieved, dexamethasone was safely  
discontinued and the infusion duration reduced to 1 hour.  
 
Three patients developed grade 1 cutaneous telangiectasia on the trunk early in the course of  therapy, all 
at dose levels of 10 or 15 mg/kg week ly that resulted in continuous serum levels of  TRC105 known to 
saturate CD105 sites on human endothelium. Grade 1 or 2 hemorrhage was  reported, including intermittent 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   11 
 postcoital vaginal bleeding (that also occurred prior to TRC105  treatment), epi[INVESTIGATOR_3940], an d superficial gingival 
bleeding  
  
Grade 1 or 2 headaches were observed, mainly in patients treated at doses of TRC105 above 3  mg/kg.  
Headaches began the day following infusi on and were generally manageable with acetaminophen. 
However, grade 2 headache  in one patient at 15 mg/kg weekly prompted  discontinuation prior to completion 
of the dose -limiting toxicity evaluation period. Fatigue was  one of the more common adverse events 
attributable to TRC105 and was more prevalent at doses above 3 mg/kg.  
 
One patien t developed dose -limiting toxicity of grade 4 hemorrhage presenting as melena from a  gastric 
ulcer within 5 days of the initial TRC105 infusion at 0.1 mg/kg. He discontinued  TRC105 treatment, was 
transfused 2 units of packed red blood cells and the bleedin g resolved  with nonsurgical management by 
[CONTACT_28107]. Serious bleeding was not  observed following protocol amendment to exclude 
patients with a history of peptic ulcer disease  (unless healing was documented) and patients on ulcerogenic 
medications including nonsteroidal  anti-inflammatory drugs.  
 
Classic toxicities associated with VEGF inhibition, including hypertension, proteinuria and  thrombosis were 
not prominent. One patient with recurrent anal cancer treated at 0.1 mg/kg  developed prote inuria 
considered possibly related to TRC105, but proteinuria was also noted  prior to TRC105 dosing. Transient 
hypertension (156/112) without QT changes occurred in a  single patient one day following infusion of 15 
mg/kg, and was controlled by a single dos e of oral antihypertensive medication. There were no arterial or 
venous thromboembolic events, nor  gastrointestinal or other perforations in these patients.  
 
 
Potential Risks of TRC105  
 
Grade [ADDRESS_741356] 
been the source of g ingival bleeding and epi[INVESTIGATOR_3940].  Telangiectasia are also seen in patients with hereditary 
hemorrhagic telangiectasia (HHT), a disease of CD105 haplotype insufficiency.  Patients with HHT are at 
risk of hemorrhage from abnormal blood vessels and this could be exacerbated by [CONTACT_28112]105.  
Other contraindications to TRC105 therapy include a history of significant hemorrhage or tumors located in 
the central chest or another location where bleeding is associated with high morbidity.  All patients treat ed 
with TRC105 should be monitored for signs of hemorrhage and the risks and benefits of drug treatment 
reevaluated in any patient with hemorrhage.  
 
Premedication including the use of glucocorticoids is required prior to infusion of TRC105 to reduce the 
frequency and severity of infusion reactions.  Infusion reactions following TRC105 dosing generally occur 
with the first TRC105 dose and include a grade 4 vasovagal reaction that resolved without sequellae.  Signs 
and symptoms of TRC105 infusion reactions in clude hypertension, hypotension, dyspnea, bronchospasm, 
chills/rigors, chills, sweats, fever, nausea, tachycardia, bradycardia, EKG changes, flushing, urticaria, 
pruritus, and headache, generally of grade 1 and 2 severity. Potential infusion reactions seen  with other 
therapeutic antibodies include angioedema, asthenia, throat irritation, rhinitis, vomiting, joint pain, fatigue 
and neurologic disorders including inflammation of the spi[INVESTIGATOR_20793]/or brain.  
 
Hypersensitivity reactions with infusions are a potenti al risk for sensitized patients, and TRC105 should be 
used with caution in patients with known hypersensitivity to any component of the drug product.  Host anti -
TRC105 antibodies to the murine or human portions of CHO -produced TRC105 are rare.  In general,  the 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   12 
 risk of immunogenicity to therapeutic chimeric antibodies is small (<10%) and the clinical significance of 
immunogenicity is not well defined.   
 
Grade 3 cerebrovascular hemorrhage resulting in hemiparesis occurred in one patient with hepatocellular 
cancer who was thrombocytopenic (who entered the study with a platelet count of 60,000/uL) in a study of 
TRC105 with sorafenib.  Patients must have a platelet count of > 100,000/uL to enter this study (see 
inclusion criteria). A grade [ADDRESS_741357] patient with glioblastoma with a history of recurrent meningitis developed recurrent grade 3 bacterial 
meningitis while treated with bevacizumab and TRC105.  
 
Grade 3 myocardial infarction (non -Q wave infarct associated with hypertension following an infusion 
reaction) was observed in a patient with hepatocellular cancer following treatment with TRC105 that 
resolved without sequellae.  In addition, a Grade 5 myocardial infarction occurred in a patient with coronary 
artery disease who recei ved TRC105 in combination with sorafenib. Patients with evidence of active 
coronary artery disease are excluded from participation in this trial (see exclusion criteria).   
 
Adult respi[INVESTIGATOR_564427]105 with pazopanib, from which the patient recovered. Of note, interstitial lung disease has been added 
as an adverse drug reaction and warning/precaution to the core safety information for pazopanib. 
Pneumothorax (collapsed lu ng) has been observed in trials of TRC105 administered with VEGF inhibitors 
in patients with lung metastases. In addition, pnemothorax was observed in one patient, also with lung 
metastases, receiving single -agent TRC105.  
 
Infections have been observed rar ely. Grade 3 infected lipoma/cyst was observed in a Phase [ADDRESS_741358] been observed in fewer than 5% of patients and have largely been considered 
unrelated to treatment with TR C105. Reversible grade [ADDRESS_741359] radiographic response reported outcome in 21 of 45 patients.   
Decreases in CEA, PSA, or CA -125 were noted in 7 of 21 patients (33%) and a global decrease in key 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   13 
 angiogenic biom arkers was observed with  treatment. One patient with castrate -refractory prostate cancer 
has remained on TRC105 treatment  for 9 years at a TRC105 dose of 0.01 mg/kg every [ADDRESS_741360] 3+3 phase I design and treated a total of 20 patients.  No dose limiting toxicity (DLT) was 
identified.  The maximum d ose tested of 20 mg/kg every 2 weeks was declared the maximum tolerated 
dose (MTD).  Common adverse effects included infusion -related reaction (90%), low grade headache 
(67%), anemia (48%), epi[INVESTIGATOR_3940] (43%) and fever (43%). Ten patients had stable disease o n study and eight 
patients had declines in prostate specific antigen (PSA). Vascular endothelial growth factor (VEGF) was 
increased after treatment with TRC105 . 
1.6 Rationale  
The Bhowmick laboratory has shown  that TRC105 inhibits multiple biochemical changes t hat promote the 
onset of resistance to AR -targeted therapi[INVESTIGATOR_014].  Models of AR inhibition  (blocking androgen synthesis and 
androgen receptor antagonism) result in CD105 upregulation in prostate cancer epi[INVESTIGATOR_564428]. CD105 expression c an stimulate tumor vascular and fibroblast proliferation as well as mediate 
tumor expression of androgen receptor variants resistant to AR-targeted therapi[INVESTIGATOR_014] . TRC105, as a single 
agent, was not inhibitory to PCa expansion in CRPC patients  [42]. Accordingly, we an ticipate a combination 
of AR-targeted therapy  (enzalutamide or a biraterone) with TRC105 (in patients with rising PSA) will inhibit 
PCa tumor progression. In tissue cultu re and tissue recombination studies in mice, CD105 was elevated 
with enzalutamide treatment and importantly was suppressed with TRC105 treatment. Similarly,  human 
PCa xenograft ed castrated mice  treated with TRC105, demonstrated  decreased tumor volume  compa red 
to castration alone (similar to a biraterone) or castration plus e nzalutamide. In tumor tissues of mice treated 
with TRC105, tumor epi[INVESTIGATOR_564429] a decrease in  neuroendocrine differentiation - a suspected mode 
of resistance to AR -targeted therap y. Furthermore, TRC105 treatment decreased the expression of AR 
therapy -induced splice variant  generation  (AR-V7) in PCa epi[INVESTIGATOR_564430]. Such expression of 
androgen receptor splice variants lacking the ligand binding domain are transcriptionally  active in the 
context of AR-targeted therapi[INVESTIGATOR_014] . This data supports the use of TRC105 in combination with AR-targeted 
therapi[INVESTIGATOR_014] (enzalutamide or a biraterone) to suppress factors promoting resistance to AR -targeted therapi[INVESTIGATOR_564431].  
 
Hypotheses  
In light of the above findings, we hypothesize that i nhibition of CD105 can overcome resistance to AR 
targeted therapy  inducing clinical benefit (including PSA decline) in pat ients who have developed early 
resistance to AR -targeted therapy  
 
To test this hypothesis, we will conduct a clinical trial to test the addition to TRC105  to two existing AR -
targeted therapi[INVESTIGATOR_564432]: abiraterone and  enzalutamide.  
  
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   14 
 2.0 STUDY OBJECTIVES  
2.1 Primary Objectives  
 To measure  clinical benefit  of TRC105 with enzalutamide or with abiraterone  in patients who 
have demonstrated resistance  by [CONTACT_564455].  
2.2 Secondary Objectives   
 Describe the adverse events associated with TRC105 and abiraterone or enzalutamide.  
 Measure the impact of the addition of TRC105 to abiraterone or enzalutamide on serum PSA 
concentration . 
 Measure the effect of the addition of TRC105 to abiraterone or enza lutamide by [CONTACT_564469] (RECIST, Prostate Cancer Working Group 3 ( PCWG 3)[43]) after 2  and 4  months . 
 Measure the proportion of patients who remain progression free by [CONTACT_62649]/or radiographic 
measurement at 2 and 4 months after the addition of TRC105 to abiraterone or enzalutamide  
2.3 Exploratory Objectives  
 When possible, to obtain archival biopsy tissue specimens o n primary tumor and subsequent 
metastasis biopsies preceding the current trial.  
 Measure the  impact of the ad dition of TRC 105 to abiraterone on serum DHEA -S and other 
steroid metabolites and/or intermediates.  
 Measure  the impact of the addition of TRC 105 to enzalutamide on serum testosterone  and 
other steroid metabolites and/or intermediates.  
 Measure th e impact of  the addition of TRC 105 to enzalutamide or abiraterone on PFA (platelet 
function).  
 To associate changes in biomarkers with clinical behavior on combination therapy including  
Nanovelcro and CellSearch CTCs and associated subsets  within the CTCs   
 rtPCR for AR status (full length AR and variants AR -V7, AR -v567es, AR -V1, AR45, 
and AR -V3) 
 Immunofluorescence for RNPC1 , Phosphorylated -Smad1/5 and phosphorylated -
Smad2/3 , Neuropi[INVESTIGATOR_16568] , NE differentiation  markers  (Chromagranin A, Synaptophysin, 
NSE) , EMT markers (E -cadherin, N -cadherin, Snail, Twist) , sCD105  
 To associate changes in serum biomarkers with clinical behavior on combination therapy 
including  
 sCD105 ,  
 Cysteine  
 P1GF, bFGF, sVEGFR1  
 Osteopontin  
 P1NP  
 CTX 
 RANKL  
 PTHrP, PTH  
 OPG  
 To associate changes in cells within  the buffy coat with  clinical behavior on combination therapy 
including  
 T cells (CD4, CD8, activation markers, and PD -1) 
 Monocytes expanded and differentiated to macrophage  (CD68, CD206 (M2), 
CD62(activation), MHC class II (M1))  
 When possible, to associate  tissue changes and biomarker expression with clinical outcomes 
including:  
 Proliferation  (by [CONTACT_15915]67)  
 Apoptosis (TUNEL, caspase -3) 
 NE differentiation  
 Biochemical markers of stemness  
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   15 
  AR Status  
 Phosphorylated -Smad1/5  and phosphorylated -Smad2/3  
 Tumor neo -vascularization (CD31, von willbrand factor)  
 LOX (measure of hypoxia)  
 EMT markers (E -cadherin,  N-cadherin, Snail, Twist)  
3.0 ENDPOINTS  
3.1.1  Primary endpoint  
 Clinical benefit will be defined as stabilization of disease for at least 2 months or improvement 
at any tim e from the start of combination therapy by [CONTACT_564470]/or biochemical criteria.  
o Radiographic Improvement will be defined as a PR or CR by [CONTACT_393] 1.1 or 
improvement by [CONTACT_43877]3 criteria  (see section 7.1).  
o Biochemical response will be defined by [CONTACT_163898]3 criteria (see section  7.3) 
o Stabilization will be defined as the absence of progression by [CONTACT_564471]  
3.1.2  Secondary endpoint s 
 Adverse events from TRC105 and abiraterone or enzalutamide described using CTCAE 4.0  
 Measurement of progression free survival by [CONTACT_564472] (as noted above)  
 
  
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   16 
 4.0 STUDY DESIGN  
 
This is a single -institution, open -label study of TRC105 in combination with abiraterone or enzalutamide in 
patients who are taking either abiraterone or enzalutamide and showing signs of biochemical progression  
without radiographic progression .  In essence, a patient who is progression on AR -therapy will continue the 
same AR -therapy on study with the addition of TRC105. The two arms will accrue in parallel and 
independently.  
 
There will be a 2 -week washout of th e active AR -targeted therapy prior to initiation of combination therapy.  
TRC105 will be administered at 10 mg/kg weekly  for the first 4 weeks then  every two weeks  at 15 mg/kg .   
 
The first TRC105 dose will be split into two doses whereby 3 mg/kg is administered over 4 hours (+/ - 15 
minutes) on Cycle 1 Day 1 and the balance is administered on Cycle 1 Day 4.   
5.0 PATIENT ELIGIBILITY  
5.1 Inclusion Criteria  
1. History of metastatic, castration -resistant prostate cancer with rising PSA on either abiraterone or 
enzalutamide  
a. PSA rise will be defined as an increase in PSA of 0.2 ng/mL or higher on at least [ADDRESS_741361], the patient will still be considered eligible.  
2. ECOG 0 -2 
3. Resolution of adverse events results from prior cancer  therapi[INVESTIGATOR_52276] 1 OR 
baseline  with the exception of the laboratory tests specified below.  
4. Adequate organ function defined by:  
 AST and ALT < 2.[ADDRESS_741362]  
 Total serum bilirubin < 1.[ADDRESS_741363]  
 Platelets > 100K  
 Hgb > 8 .5 g/dL 
 Serum Cr <1.[ADDRESS_741364]  
 INR 0. 8 – 1.[ADDRESS_741365] doses of abiraterone (1000 mg daily) or enza lutamide (160 mg daily).  
3. Other prior malignancy requiring active anticancer therapy  
4. Prior exposure to TRC105 or any CD105 targeted antibody  
5. Any major surgical procedure within 2 weeks of starting therapy  
6. Uncontrolled chronic hypertension defined b y systolic pressure (SBP) > 150 mmHg or diastolic 
pressure (DBP) >[ADDRESS_741366] 6 months.  An acute cardiovascular event will be defined 
as a m yocardial  infraction , NYHA Class II or worse  congestive  heart failure, cerebrovascular 
accident, transient ischemic attack, arterial embolism, pulmonary embolism, percutaneous 
transluminal coronary angioplasty ( PTCA ), or CABG. Deep venous thrombosis within [ADDRESS_741367] dose of TRC105.  Th e definition of effective contraception will be 
based on the judgment of the Principal Investigat[INVESTIGATOR_1660] [INVESTIGATOR_1660] a designated associate .  Abstinence from 
intercourse is an acceptable form of contraception.  
6.0 TREATMENT PLAN  
6.1 Washout for AR -targeted agents  
To maximally “reset” AR -driven signaling, patients will be required to have a washout of the AR -targeted 
agent prior to starting study treatment.   Pre-clinical studies demonstrated an induction of CD105 following 
androgen targeted therapy given to naïve tumors. This su ggests that TRC105 effects may be maximized 
following a washout period. This washout period will consist of at least 2 weeks prior to starting combination 
therapy.   
6.2 Dosing plan  
Table 1.  Dosing of AR agent and TRC105  
AR Agent at ent ry AR agent dose  TRC105 dose 
(weeks 1 -4) TRC105 dose  
(weeks 5 +)  
Abiraterone  Abiraterone 1000 mg daily  10 mg/kg weekly  15 mg/kg every two weeks  
Enzalutamide  Enzalutamide 160 mg daily  10 mg/kg weekly  15 mg/kg every two weeks  
 
6.3 Investigational compound  
Composition of TRC105  
TRC105 is an IgG1, kappa immunoglobulin containing murine light - and heavy -chain variable  
region sequences and human constant region sequences. TRC105 has an approximate molecular weight 
of 148 kDa.  
 
TRC105 Packaging and Labeling  
TRC105 may be provided in one or more of the following presentations.  
Phosphate Buffered Saline Formulation (7 mg TRC105/mL)   
210 mg TRC105/30 mL single -use vial  
20 mM L -Histidine/L -Histidine Monohydrochloride, 240 mM Trehalose, 0.01% Polysorbate 20 
Formul ation (25 mg TRC105/mL)  
100 mg TRC105/4 mL single -use vial  
200 mg TRC105/8 mL single -use vial  
400 mg TRC105/[ADDRESS_741368] be stored upright between 2 °C and 8 °C (36 °F to 46 °F)  and protected from light  
 
TRC105 Preparation  
TRC105 will be prepared in the pharmacy and diluted into normal saline using appropriate aseptic 
technique . TRC105 will be administered using an in -line 0.[ADDRESS_741369] been observed.  Multiple vials will be required for a 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   18 
 single dose.  The following formulae should be used to calculate the volume of TRC105 to be added to 
normal saline:  
 
Patient weight (kg) × dose level (mg/kg) divided by [CONTACT_28117]105 concent ration (mg/mL) = volume of TRC105 
(mL) to be administered.  
 
The volume of TRC105 that is to be administered can be rounded up or down to the nearest 1.0 mL; in the 
case of an increment of 0.5 mL the volume should be rounded up. The maximum weight that shou ld be 
used for dose calculation for men in this study is 100 kg (note: there is not a weight restriction for 
enrollment purposes).   If the patient’s weight changes by > 10% during the study, the dose of TRC105 
will be recalculated.  At that time a new base line weight will be established such that subsequent weight 
changes by >10% from the new baseline weight would require further recalculation of the TRC105 dose. 
The calculated volume of TRC105 will be diluted with normal saline.  Appropriate judgment shoul d be 
exercised in withdrawing an adequate amount of saline necessary to permit injection of the appropriate 
volume of antibody into a normal saline bag in accordance with the dose needed.  The final TRC105 
concentration must be between 0.6 mg/mL and 10 mg/ mL.  The prepared TRC105 must be gently inverted 
several times in order to ensure a homogeneous solution. The diluted infusion solution of TRC105 should 
be used within 8 hours of preparation if stored at room temperature, or within 24 hours of dilution if stored 
at 2° to 8°C (36º to 46ºF). The expi[INVESTIGATOR_52277].  If the diluted infusion solution 
of TRC105 cannot be infused within 8 hours of preparation (i.e.: the prepared infusion is at room 
temperature for more than 8 hours), a s econd bag will be prepared that contains the balance of the planned 
dose that was not already delivered. The prepared solution should not be frozen.  
 
TRC105 Administration  
Patients should be encouraged to drink abundant fluid (e.g., two eight ounce glasses  of water or juice) prior 
to the first treatment.  Intravenous hydration prior to and during therapy is left to the discretion of the 
Investigator, but should be considered for patients that may be volume depleted.  
 
The following TRC105 premedications shou ld be administered 2 hours to 30 minutes prior to the start of 
each infusion:   
 
 Acetaminophen 650 mg p.o. x 1  
 Methylprednisolone 100 mg IV will be given prior to the cycle 1 day 1 and cycle 1 day 4 infusions.   
In addition, methylprednisolone will be giv en in the case of a delay of > 10 days between any two 
scheduled weekly doses or in the case of a delay of > 17 days between any two scheduled every 
other week doses, or if the patient develops an infusion reaction > grade 2 during the immediate 
prior infusion.  
 Famotidine 20 mg IV  or p.o. (or similar H2 blocker) x 1. Famotidine (or similar H2 blocker) may be 
discontinued starting with Cycle 3, in the absence of infusion reactions with the prior dose.  
 Cetirizine 10 mg  IV or p.o. x 1 (or similar oral or intravenous antihistamine).  Cetirizine (or similar 
oral or intravenous antihistamine ) may be discontinued starting Cycle  3, in the absence of infusion 
reactions with the prior dose.  
 
TRC105 infusions will begin [ADDRESS_741370] weekly TRC105 dose will be split into two doses 
whereby 3 mg/kg is administered over  4 hours (+/ - 15 minutes) on Cycle 1 Day 1 and the balance is 
administered on Cycle 1 Day 4.   
 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   19 
 Patients who complete one 4-hour infusion without the development of any infusion reactions, will reduce 
the subsequent TRC105 infusion to 2 hours (+/ - 15 minut es) and patients who complete a 2-hour infusion 
without the development of any infusion reactions will reduce subsequent TRC105 infusions to 1 hour (+/ - 
15 minutes) . See Table [ADDRESS_741371] not exceed 25 mg/min.  When the IV . bag containing TRC105 is empty, 
flush the IV line with a [ADDRESS_741372] month of Qweekly dosing  and dosing 
is resumed ≥ [ADDRESS_741373] dose or if a patient misses a scheduled every 2-week  dose after Week 
5, and dosing is resumed ≥ [ADDRESS_741374] dose, premedication (including  methylprednisolone) are 
to be administered as was done with the initial TRC105 dose. Split dosing is not required. However, it is 
recommended that if the patient experienced a severe headache with a previous infusion,  the first TRC105 
dose upon resumption should be administered over two days as was done for the initial dose . 
 
Table 2.  TRC105 doses and schedules for Dose Level A1/E1  
 C1D1  C1D4  C1D8  C1D15  C1D22  C2D1  C2D15  C3D1+  
TRC105 Dose (mg/kg)  3 7 10 10 10 15 15 15 
Infusion Duration (hours)  4 2 1 1 1 1 1 1 
Premedication  
Methylprednisolone (mg)  100 100 0 0 0 0 0 0 
Famotidine (mg)  20 20 20 20 20 20 20 0* 
Cetirizine (mg)  10 10 10 10 10 10 10 0* 
Acetaminophen (mg)  650 650 650 650 650 650 650 650 
 
*  in the absence of infusion reactions with the prior dose, cetirizine and famotidine may be discontinued 
starting at cycle [ADDRESS_741375] ered as indicated.  For grade 2 and certain grade 3 infusion 
reactions, the infusion may be restarted (the same day) at half of the previous rate after the infusion reaction 
has resolved, then increased per patient tolerance to a maximum of 25 mg/min. For grade 4 infusion 
reactions, the infusion should not be restarted and the patient should be discontinued from study treatment. 
Infusion reactions will be recorded as AEs in the case report form.  
  
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   20 
  
Infusion reaction 
severity  Recommended management  
Grade 1  No intervention .  Continue infusion unless symptoms worsen  
Grade 2  1. Interrupt infusion  
2. Treat with symptomatic medications  
3. Resume infusion at half the previous rate when infusion -related 
symptoms improve to grade 1 or less  
Grade 3  1. Interrupt infusion  
2. Treat with symptomatic medications  
3. Monitor patient until infusion -related symptoms resolve, including 
hospi[INVESTIGATOR_17116]  
4. Withdraw patient from study unless other factors that contributed to the 
infusion reaction are identified and corrected  
Grade 4  1. Discontinue infusion  
2. Treat with symptomatic medications  
3. Hospi[INVESTIGATOR_28068]  
4. Withdraw from study  
 
Symptomatic medications may include but are not limited to  
 diphenhydramine 50 mg i.v. and/or hydrocortisone 100 mg i.v. (for f ever, rash, hypoxia, or other 
hypersensitivity reactions)  
 meperidine 50 -100 mg i.v. (for shaking chills/rigors),  
 oxygen by [CONTACT_28119] (for hypoxia),  
 epi[INVESTIGATOR_238] 0.5 mg i.m. (for hypotension or bronchospasm),  
 albuterol inhaler or nebulizer (for bronchospasm),  
 i.v. fluids (for hypotension),  
 ondansetron 0.15 mg/kg i.v. (for nausea).  
 
The Investigator must maintain an accurate accounting of TRC105 supplied by [CONTACT_564473] . 
During the study, the following information m ust be recorded:  
 Date of receipt, quantity and lot number of the TRC105 study drug received from Tracon  
 ID number of the patient to whom the product is dispensed  
 The date(s) and quantity of the product dispensed  
 Dates and quantity of product returned, lost  or accidentally or deliberately destroyed  
6.[ADDRESS_741376] of care therapy.  
 
Investigational pharmacy will not be responsible fo r drug accountability of these agents.  Patients will be 
asked to maintain a pi[INVESTIGATOR_564433].  
6.5 Toxicities and Dosing Delays/Dose Modifications  
6.5.1  AR Therapy  
Dose modifications to AR -therapy will not be allowed.  
6.5.2  TRC105 Dose Reduction/Do se Interruptions  
TRC105 dose reductions and interruptions should be avoided in cycle 1. In cycle 2 and beyond,  TRC105 
dose reductions are allowed  using the guidelines below.  TRC105 should be held for two weeks prior and 
for two weeks following surgical  procedures.  However, resumption of study treatment can be shorter (but 
no less than 7 days) or longer than two weeks based on clinical judgement  of the treating investigator  of 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   21 
 adequate wound healing and recovery from the procedure. For minor procedures (e.g ., port placement), 
TRC105 should be held for at least [ADDRESS_741377] 1 week after (or until adequate healing).  
 
Toxicity Attributed to 
TRC105  Dose Adjustment for Next Dose of TRC105  
(% of Starting Dose)  
Grade 1  Maintain dose  
Grade 2  At the discretion of the treating investigator, 
dose may be maintained or decreased to  80%  
Grade [ADDRESS_741378] appearance  Decrease to 80%  
  - second appearance  Decrease to 60%  
  - third appearance  Discontinue TRC105 permanently  
6.6 Concomitant Medications/Treatments  
No other approved or investigational anticancer treatment will be permitted during the study  period  with the 
exception of primary medical castration therapy (i.e. LHRH analogs) . No other investigational drug may be 
used during treatm ent on this protocol, and  concurrent participation in another clinical trial is not allowed.  
 
Patients who are on abiraterone as part of this study should continue to use prednisone 5 mg twice daily or 
an equivalent adrenal androgen supplement at the treating investigator’s discretion.  This dose should be 
stable from the patient’s previous utilization of steroid while on abiraterone.   
 
Patients who receive NSAIDs on study may also receive peptic ulcer disease (PUD)  prophylaxis with an 
H2 or proton pum p blocker.  
 
Narcotic analgesics, nonsteroidal anti -inflammatory drugs, and triptans (e.g. sumatriptan) may be  offered 
as needed for relief of pain or headaches. Antihistamines and decongestants may be  offered for the 
treatment of sinus congestion.  
 
Packed red blood cell, colony stimulating factors, and platelet transfusions should be  administered as 
clinically indicated.  
 
Patients with arterial thrombosis or grade [ADDRESS_741379] their  TRC105 therapy 
interrupted. TRC105 therapy may resume once the following criteria are met:  
 The patient is on a stable dose of heparin or low molecular weight heparin or Factor X inhibitor.  
 The patient h as a platelet count > 100,000.  
 The patient has not had a hemorrhagic event of grade 2 or higher while on study.  
 The patient does not have a pathological condition that carries a high risk of bleeding (e.g., 
tumor involving major vessels).  
 The patient is benefiting from TRC105 therapy (no evidence of disease progression).  
6.7 Duration of Therapy  
Therapy will continue until  one of the following:  
 Disease progression by [CONTACT_564474] (verified by [CONTACT_564475] 4 weeks later).  A 
treating physician may continue TRC105 therapy if it is felt that there is clinical benefit despi[INVESTIGATOR_564434] . 
 Patient withdrawal  
 Excessive toxicity  
 Death  
6.[ADDRESS_741380] dose of study medication, with the 
allowance for those reasons noted in protocol Section  6.11.3  
6.9 Removal of Patients from Protocol  
Patients will be removed from the study  when any of the criteria listed in Section 6.13 apply . Notify the 
Principal Investigator, and document the reason for study removal and the date the patient was removed 
in the Case Report Form . The patient should be followed -up per protocol .  
6.10 Patient Replacement  
Patients will not be considered assessable (and hence can be replaced), if they are unable to be assessed 
for clinical benefit at 8 weeks by [CONTACT_62649]/ or scans.  
6.[ADDRESS_741381] of any study -related procedures. 
During this phase the following will be completed as specified in the Time and Event Table:  
 
 Informed Consent  
 Investigator’s Confirmation of Eligibility  
 Demographics  
 Medical/Surgic al History , including treatment history for PCa  
 Baseline Physical Exam  including Performance Status (ECOG)  
 Vital Signs  
 PSA 
 CTC  
 Serum Testosterone  
 Urinalysis ( w/microscopic examination)  
 Baseline CT/MRI (Chest CAP or CT Chest/MRI AP)  
 Bone Scan  (Tc-99 or NaF ) 
 Chemistry  
 Hematology  
 Concomitant Medications (within 30 days of C1D1)  
6.11.[ADDRESS_741382] dose of study drug for all subjects, except the 
following:  
 Patient is lost to follow up  
 Patient is deceased  
 Patient has withdrawn consent for study participation.  
 Patient is unable to return to study site  
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   23 
 6.12 Time and Events Table  
 
  
Screening  C1D1  C1D4  C1D15  Day 1 each 
subsequent 
cycle 
(+/- 7) Day 15 
each 
subsequent 
cycle (+/ - 
7) EOT 
30 days 
after 
treatment 
d/c 
(+/- 7) 
Informed Consent  X       
Medical History & 
Demographics  X       
History & Physical1 X X  X X X X 
Vital signs2 X X X X X X X 
Adverse events   X  X X X  
Concomitant 
Medications  X X  X X X  
CT or MRI and Bone3 
Scan  X Every 8 weeks from C1D1    
TRC105 dosing6  X X X X X  
AR Inhibitor therapy   Continuous daily dosing starting on Cycle 1 Day 1   
CBC w/diff  X X  X X X X 
Serum Chemistry4 X X  X X  X 
Testosterone, CTC,  
PSA X X  X X  X 
Urinalysis with 
microscopic exam5 X X   X   
Research blood 
collection  X X   X  X 
 1 Documentation should include performance status using ECOG scoring system  
2 Vital signs to include heart rate, temperature, blood pressure, respi[INVESTIGATOR_697] (Height will be assessed during screening only)  
[ADDRESS_741383], LDH (no LDH on C1D15)  
5 Additional urine studies such as protein and/or creatinine should be performed as clinically indicated  
[ADDRESS_741384] cycle dosing schedule.  
 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   24 
 6.13 Removal of Subjects from Study  
Patients can be taken off the study treatment and/or study at any time at their own request, or they may be 
withdrawn at the discretion of the investigator for safety, behavioral or administrative reasons. The 
reason(s) for discontinuation will be documented and may include:  
 Patient voluntarily withdraws (follow -up permitted);  
 Patient withdraws consent (termination of treatment and follow -up); 
 Patient is unable to comply with protocol requirements;  
 Patient demonstrates disease progression (unless continued treatment with stud y drug is 
deemed appropriate at the discretion of the investigator);  
 Patient experiences toxicity that makes continuation in the protocol unsafe;  
 Treating physician judges continuation on the study would not be in the patient’s best interest;  
 Development o f second malignancy (except for basal cell carcinoma or squamous cell 
carcinoma of the skin) that requires treatment, which would interfere with this study;  
 Lost to follow -up. 
 
 
 
  
IIT201 6-16-POSADAS -TRC105  
Protocol Version [ADDRESS_741385] agree 
to using this as the imaging modality for all soft -tissue tumor assessments for all protocol required imaging 
studies.  
7.1.1  Bone scan evaluation  
Prostate cancer working group 3  (PCWG3 ) criteria will be used to evaluate bone scans .   In brief, 
progressive disease will be defined by [CONTACT_2669] [ADDRESS_741386]/MRI Assessments: RECIST 1.1  
Response and progression will be evaluated in this study using  new response evaluation criteria in solid 
tumors: Revised RECIST guideline (version 1.1) [44]. 
7.[ADDRESS_741387] one dimension (longest diameter in the plane of 
measurement is to be recorded) with a minimum size of 10mm by [CONTACT_5711]. To be measurable a 
lymph node must be >15mm in short axis when assessed by [CONTACT_564476].  
All tumor measurements must be recorded in millimeters . 
 
Note: Previously irradiated lesions are non -measurable except in cases of documented progression of the 
lesion since the completion of radiation therapy.  
 
Non-measurable disease .  
All other lesions, including small lesions (longest diameter<10mm or pathological lymph nodes with >10 to 
<15mm short axis) as well as truly non -measurable lesions are considered non -measurable disease.  
 
Target lesions. All measurable lesions up to a maximum of 2 le sions per organ system and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions  and recorded and 
measured at baseline. Target lesions should be selected on the basis of their size (lesions with the longest 
diame ter) and their suitability for accurate repeated measurements (either by [CONTACT_15078]). A sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the b aseline sum diameters.  
 
The baseline sum diameters  will be used as reference by [CONTACT_204667] . 
 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   26 
 Non-target lesions . All other lesions (or sites of disease) including any measurable lesions over and above 
the [ADDRESS_741388] of a treatment.  
7.2.3  Response Criteria  
 
Evaluation of Target Lesions  
Complete Response (CR) : Disappearance of all target lesions, determined by [CONTACT_564477] 4 weeks apart. There can be no appearance of new lesions.  
 
Partial Response (PR) : At least a 30% decrease in the sum of the diameters of target lesions, taking as 
reference the baseline sum. There can be no appearance o f new lesions.  
 
Progressive Disease (PD) : At least a 20% increase in the sum of the diameters of target lesions plus an 
absolute increase of at least [ADDRESS_741389] sum recorded since the start of studys.   
 
Stable Disease (SD) : Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, 
taking as reference the smallest sum of diameters since the treatment started.  
 
Evaluation of Best Overall Response  
The best overall response is the best response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements recorded 
since the treatment started). The patient's best response assignment will depend on the achievemen t of 
both measurement and confirmation criteria.  
 
Duration of Response  
Duration of overall response : The duration of overall response is measured from the time measurement 
criteria are met for CR or PR (whichever is first recorded) until the first date tha t recurrent or progressive 
disease is objectively documented (taking as reference for progressive disease the smallest measurements 
recorded since the treatment started).  
 
The duration of overall CR is measured from the time measurement criteria are first met for CR until the 
first date that recurrent disease is objectively documented.   
 
Duration of stable disease : Stable disease is measured from the start of the treatment until the criteria for 
progression are met, taking as reference the smallest measurem ents recorded since the treatment started.  
 
Progression -Free Survival  
Progression -free survival (PFS) is defined as the duration of time from start of treatment to time of 
progression.  
  
IIT201 6-16-POSADAS -TRC105  
Protocol Version [ADDRESS_741390] dec ision making based on PSA changes, given the unique 
hypothesis, PSA will be tracked and considered actionable.   
 Responses will be considered any PSA value >50% below baseline .   
 Progression will be defined as a rise in serum PSA that is ≥ 25% and 2 ng/mL above nadir which 
is confirmed by a second value ≥ 3 weeks later.  
 Stabilization of disease refers to PSA values that do not meet criteria for progression  
7.4 Safety/tolerability  
Analyses will be performed for all patients having received at least one dose of study drug. The study will 
use the CTCAE version 4.0 for reporting of adverse events ( http://ctep.cancer.gov/reporting/ctc.html ) 
and modified criteria for hematologic adverse events  
 
IIT201 6-16-POSADAS -TRC105  
Protocol Version [ADDRESS_741391] be reported in an expedited manner to allow for optimal 
monitoring of patient safety and care .  
 
AEs (serious and nonserious) will be collected and recorded beginning with the administration of Cycle [ADDRESS_741392] administratio n of study treatment. If a patient begins a new 
anticancer therapy, the AE reporting period for nonserious AEs ends at the time the new treatment is 
started.  
 
All patients experiencing an adverse event, regardless of its relationship to study drug, will be  monitored 
until:  
 the adverse event resolves or the symptoms or signs that constitute the adverse event return 
to grade 1 or baseline  
 any clinically significant abnormal laboratory values have returned to grade 1 or baseline  
 there is a satisfactory explanation other than the study drug for the changes observed  
 death  
8.2 Definitions  
8.2.1  Definition of Adverse Event  
An adverse event (AE) is any untoward medical occurrence in a patient receiving study treatment and which 
does not necessarily have a causal relati onship with this treatment. An AE can therefore be any unfavorable 
and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of an experimental intervention, whether or not related to the interve ntion.  
 
Abnormal Test Findings  
Laboratory test and diagnostic studies (e.g. cardiac testing) which meet the following criteria must be 
reported as  an AE:  
 Test result is determined to be clinically significant by [CONTACT_564478]  
 Test result  requires medical/surgical intervention  
 
8.2.2  Severity of Adverse Events  
All adverse events will be graded according to the NCI Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0. The CTCAE v4 is available at http://ctep.cancer.gov/reporting/ctc.html  
 
If no CTCAE grading is available, the severity of an AE is graded as follows:  
 Mild (grade 1):  the event causes discomfort without disruption of normal daily activities.  
 Moderate (grade 2):  the event causes discomfort that affects normal daily activities.  
 Severe (grade 3):  the event makes the patient unable to perform normal daily activities or 
significantly affects his/her clinical status.  
 Life-threatening (grade 4):  the patient was at risk of  death at the time of the event.  
 Fatal (grade 5):  the event caused death.  
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   29 
 8.2.3  Serious Adverse Events  
A “serious” adverse event is any untoward medical occurrence that:  
 Results in death: If death results from (progression of) the disease, the disease should not  be 
reported as event (SAE) itself.  
 Is life -threatening: (the patient was at risk of death at the time of the event; it does not refer to 
an event that hypothetically might have caused death if it were more severe).  
 Requires in -patient hospi[INVESTIGATOR_26109] p rolongation of existing hospi[INVESTIGATOR_272] ≥ 24 hours.  
 Results in persistent or significant disability or incapacity.  
 Is a congenital anomaly/birth defect  
 Is an important medical event  
  
Any event that does not meet the above criteria, but that in the judg ment of the investigator jeopardizes the 
patient  may be considered for reporting as a serious adverse event. Steps  to Determine If an Adverse Event 
Requires Expedited Reporting  
 
Step 1 : Identify the type of adverse event using the NCI Common Terminology Cr iteria for Adverse Events 
(CTCAE v4) .  
 
Step 2 : Grade the adverse event using the NCI CTCAE v4.  
 
Step 3 : Determine whether the adverse event is related to the protocol therapy  
Attribution categories are as follows:  
 Definite – The AE is clearly related  to the study treatment.  
 Probable – The AE is likely related to the study treatment.  
 Possible – The AE may be related  to the study treatment.  
 Unlikely – The AE is doubtfully related  to the study treatment.  
 Unrelated – The AE is clearly NOT related  to the study treatment.  
 
Note : This includes all events that occur within [ADDRESS_741393] dose of treatment and is attributed (possibly, probably, or 
definitely) to the  agent(s) must also be reported accordingly.  
 
Step 4 :  Determine the prior experience of the adverse event .  
Expected events are those that have been previously identified as resulting from administration of the agent . 
An adverse event is considered unexpe cted, for expedited reporting purposes only, when either the type of 
event or the severity of the event is not listed in:  
 the current known adverse events listed in section 1.4 
 the drug package insert  
 the current Investigator’s Brochure  
8.3 Reporting Requirements for Adverse Events  
8.3.1  Expedited Reporting  
 The Principal Investigator [INVESTIGATOR_9960] [ADDRESS_741394] administration of the 
study drug  
  
Phone Number for Expedited Reporting:  Edwin Posadas, MD 310 -423-7600  
 
 The CSMC IRB must be notified within 10 business days of “any unanti cipated problems involving risk 
to subjects or others” (UPR/UPI[INVESTIGATOR_9961])  
 
 
 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   30 
  
The following events meet the definition of UPR:  
 Any serious event (injuries, side effects, deaths or other problems), which in the opi[INVESTIGATOR_564435], involved risk to subjects or others, and was possibly 
related to the research procedures.  
 Any serious accidental or unintentional change to the IRB -approved protocol that alters the 
level of risk.  
 Any deviation from the protocol taken withou t prior IRB review to eliminate apparent immediate 
hazard to a research subject.  
 Any new information (e.g., publication, safety monitoring report, updated sponsor safety 
report), interim result or other finding that indicates an unexpected change to the ri sk/benefit 
ratio for the research.  
 Any breach in confidentiality that may involve risk to the subject or others.  
 Any complaint of a subject that indicates an unanticipated risk or that cannot be resolved by 
[CONTACT_079].  
 
 Reporting to the Foo d and Drug Administration  
The investigator or his designee must submit SAEs on FDA Form 3500A (MedWatch) according to 
the following reporting criteria:  
 Reporting any unexpected fatal or life -threatening suspected adverse reactions no later than 
7 calendar days after initial receipt of the information . 
 Reporting any (1) serious, unexpected suspected adverse reactions, (2) findings from other 
clinical, animal, or in -vitro studies that suggest significant human risk, and (3) a clinically 
important increase in the rate of a serious suspected adverse reaction no later than 15 
calendar days after determining that the information qualifies for reporting . 
8.3.2  Reporting to TRACON  
 Pregnancy  
Although not itself an SAE, pregnancy will be reported to TRACON and followed up t o determine 
outcome, including spontaneous or voluntary termination, details of birth, and the presence or absence of 
any birth defects or congenital abnormalities.  
 
 Serious Adverse Events  
SAEs  will be repor ted to TRACON no later than 7 business  days after initial receipt of the information . 
8.4 Stoppi[INVESTIGATOR_564436] 2 portion of the study stoppi[INVESTIGATOR_564437] y and  futility will be utilized. For safety, we will 
use a Bayesian continuous monitoring design testing for evidence of a high t oxicity rate. Specifically, using 
a uniform prior for the probability of toxicity pT, we stop the trial if P( pT > 0.4 |data) > 0.7, that is if the 
posterior probability that the  probability of toxicity is greater than 40% given the data is greater than 0. 7. 
Stoppi[INVESTIGATOR_564438].  
  
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   31 
  
9.0 CORRELATIVES/SPECIAL STUDIES  
 
Details of analyses are listed in the laboratory manual.  
9.1 Correlative Studies  
The following exploratory correlatives will be examined as part of this study  (listed in order of prioritization) : 
 
Tissue  Study/biomarker  
CTCs  PCR: AR,  AR variants  
IHC: CD105, phosphorylated -SMAD 1/5 , NE differentiation markers 
(Chromagranin A, Synaptophysin, NSE) , RNPC1,  phosphorylated -Smad2/3,  
total/phosphorylated -STAT -3, YAP,  PD-L1, HEY, HES, EMT markers (E -
cadherin, N -cadherin, Snail, Twist),  
Plasma  soluble CD105,  soluble Jag, cysteine , VEGF, IL -6, P1GF, bFGF, sVEGFR1, 
osteopontin, P1NP, CTX, RANKL, PTHrP, PTH, OPG  
WBC (Buffy Coat)  phosphorylated -SMAD 1/5, HEY/HES, TAK1  
T cells (Buffy Coat)  CD3, CD4, CD8, CD25, CD28, CD69, PD1  
Monocytes (Buffy 
Coat)  CD68, CD206 (M2), CD62(activation), MHC class II (M1)  
Tissue biopsy  
(when available and 
feasible)  PCR: AR variants  
IHC: CD31, CD105, phosphorylated -SMAD 1/5 , NE differentiation markers 
(Chromagranin A, Synaptophysin, NSE), RNPC1,  total/phosphorylated -STAT -
3, YAP,  HEY, HES, phosphorylated -Smad2/3, Ki67, TUNEL , stemness 
markers,  LOX, EMT markers (E -cadherin, N -cadherin, Snail, Twist), caspase -3, 
vWF, sCD105 . 
9.[ADDRESS_741395] research kits collected consisting of the following:  
 3 yellow top (ACD) tubes - 8.5 mL (25.5 mL total)  
 1 lavender top tube (EDTA) - [ADDRESS_741396] should be similar for both agents.  As such, the clinical 
translation of this hypothesis will involve two separate but parallel phase 2 studies.  The two arms (A and 
E) will be merged for the testing of the translational hypothesis.  The two arms will be studied in the clinic 
separately to avoi d confusion due to the differences in the AR -inhibitor strategy that may not impact effect 
but may impact other clinically relevant parameters such as toxicity.  The two arms will not be compared 
for effect in the context of this clinical investigation.  
 
In discussion with Tracon, it was decided that the optimal doses for TRC105 is 15 mg/kg administered every 
2 week  following the 4 -week lead -in consisting of weekly dosing  at 10 mg/kg .   Currently Tracon has been 
using the 15 mg/kg q2week dosing in a number  of studies.  Specifically,  in prostate cancer, 20 mg/kg 
q2weeks has been tested and was found to be well tolerated.  As it is expected that there will be no 
significant interactions based on the pharmacology of agents in question as well as the preclinica l models 
from the Bhowmick laboratory, it was decided that there was no advantage to reduction of the AR -targeted 
agent doses.   
 
To optimize toxicity and effec tiveness, a Bayesian design was proposed with continuous reassessment of 
both variables over the 2 combinations.  
 
Benefit is judged by [CONTACT_564479] 2 months  [45, 46] . As all patients 
entering this study are progressing on the AR agent already, the null hypothesis will be the proportion of 
patients  who benefit will be  0%. To be conservative, we will set the null hypothesis at benefit rate of  5%.  
Conversely, the combination will be declared active if at 2 months of treatment, the proportion of patients 
who benefit is  ≥ 50% . 
 
As a matter of contrast, in a reported series, patients previously treated with abiraterone went forward to 
receive sub sequent enzalutamide  [47].  This group experienced at 63% benefit rate by [CONTACT_564480].  Median time to progression (clinical and radiographic) was 5.[ADDRESS_741397] to receive abiraterone [48].  In this group, 70% had clinical benefit by [CONTACT_564481].  Median duration of treatment was 3 months (13 weeks).  No radiographic responses  were 
reported . 
 
Additionally, if re -sensitization to AR therapy has occurred, we would expect to see stabilization or 
decreases in serum PSA concentrations.  If at 2 months, the proportion of patients with no meaningful rise 
in PSA is ≥50%, a com bination will also be considered worthy of further study.  
 
10.2 Measurement of efficacy  
The primary endpoint of these phase 2 trials is to show that the clinical benefit (CB) rate for these patients 
is at least 40% with a 5% response rate or lower being uninter esting. Let θ be the probability of CB of the 
new treatment combination. We will use a Bayesian continuous monitoring approach for testing the null 
hypothesis H 0: θ = 0.05 versus the alternative hypothesis  H1: θ > 0.05. Specifically, we will adapt the 
approach of Johnson and Cook (2009) by [CONTACT_1299] a point mass prior distribution on θ to represent the null 
hypothesis and an inverse moment prior density with mode at θ = 0.4 to represent the alternative 
hypothesis.  
 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   33 
 Johnson and Cook (2009)  [49] showed that this design has better operating characteristic than previous 
Bayesian designs which use posterior credib le intervals to define stoppi[INVESTIGATOR_564439]. When compared to Simon’s (1989) two -stage design  [50], the probabi lities of rejecting the 
experimental treatment were similar but this design uses fewer patients to reject treatments that fall below 
the target probability of response relative to Simon’s design.  
 
A maximum of 20 patients per arm will be enrolled in the tr ial. Assuming that H 0 and H 1 are equally likely a 
priori , the trial will be terminated after the nth patient for inferiority if the posterior probability of the alternative 
given the data P(H 1 |data) < 0.1. At the end of the trial, the alternative hypothes is is accepted if P(H 1 |data) 
> 0.9.  
 
Operating Characteristics:  
 
When the true probability of clinical benefit is 0.4, there is at least an 88.6% chance of concluding that the 
treatment is superior which is equivalent to the frequentist statistical power.  
 
Table 5  gives some operating characteristics for testing the above hypothesis under five scenarios for the 
“true” probability of CB θ based on 5,000 trial replications. When the true θ is 0.4, there is a 0.048 probability 
of stoppi[INVESTIGATOR_564440] θ. 
The futility boundaries for stoppi[INVESTIGATOR_564441] 6. These simulations were carried out 
using the software BFDesigner available at http://biostatistics.mdanderson.org/softwaredownload/ . 
 
 
Scenario  True θ  Pr(Stoppi[INVESTIGATOR_564442])  Average # patients treated  
(10%, 25%, 50%, 75%, 90%)  
1 0.05 0.953  10.9 (10,10,10,10,10)  
2 0.15 0.593  14.61 (10,10,10,20,20)  
3 0.25 0.261  17.58 (10,20,20,20,20)  
4 0.4 0.048  19.53 (20,20,20,20,20)  
5 0.5 0.013  19.87 (20,20,20,20,20)  
Table 5 . Operating Characteristics  
 
 
# Patients  Stop the trial for inferiority if  
there are this many successes  
10 0-1 
15 0-1 
20 0-2 
Table 6. Full Stoppi[INVESTIGATOR_274353]  
 
 
 
10.3 Safety  
Stoppi[INVESTIGATOR_564443] a patient experiences a grade 3 or higher toxicity related to the treatment 
combination. The trial will stop if there is statistical evidence that Ptox exceeds 40%. We will use a Bayesian 
sequential design by [CONTACT_564482] 5, 10, 15, and 20 patients 
are evaluable for toxicity as defined above. The decision rule is to stop the trial if the posterior probability 
that Ptox exceeds 0.40 is 0.95; P( Ptox > 0.4 | data) > 0.95. A noninformativ e prior distribution for Ptox will be 
used. Table [ADDRESS_741398], the true Ptox = 0.40. This is the equivalent of the Bayesian type I error probability. The 
target type I error probability  was set at 0.05.  
 
Number of  
Patients  Number to  
Continue  Probability to  
Stop  Cumulative Probability  
to Stop  
5 4 0.[ZIP_CODE]  0.[ZIP_CODE]  
10 7 0.[ZIP_CODE]  0.[ZIP_CODE]  
15 9 0.[ZIP_CODE]  0.[ZIP_CODE]  
20 12 0.[ZIP_CODE]  0.[ZIP_CODE]  
 
Table 7 .  Stoppi[INVESTIGATOR_564444]. Number to continue is the maximum number of toxic 
events for not stoppi[INVESTIGATOR_21356].  
 
Table 8  gives the design operating characteristics under selected values of the true probability Ptox. It gives 
the probability of stoppi[INVESTIGATOR_564445] e hypothesis, the expected sample size, and the 
average sample size given that the trial stopped. For example, if the true value of Ptox is 0.6, then there is 
an 50% chance that the trial is stopped early and the average sample size is about 16. On the oth er hand, 
there is a small chance of stoppi[INVESTIGATOR_564446]; 0.67% chance of stoppi[INVESTIGATOR_564447] 
= 0.30.  
 
True Value  
of Ptox Probability to  
Stop  Expected  
N Expected  
N given that we Stopped  
0.[ADDRESS_741399] (IRB) Approval and Consent   
It is expected that the IRB will have the proper representation and function in accordance with federally 
mandated regulations . The IRB should approve the consent form and protocol.  
 
In obtaining and documenting informed consent, the investigator should comply with the applicable 
regulatory requirement(s), and should adhere to Good Clinical Practice (GCP) and to ethica l principles that 
have their origin in the Declaration of Helsinki.  
  
Before recruitment and enrollment onto this study, the patient will be given a full explanation of the study 
and will be given the opportunity to review the consent form. Each consent fo rm must include all the relevant 
elements currently required by [CONTACT_44316]. Once this essential 
information has been provided to the patient and the investigator is assured that the patient understands 
the implicatio ns of participating in the study, the patient will be asked to give consent to participate in the 
study by [CONTACT_10001] -approved consent form.  
 
Prior to a patient’s participation in the trial, the written informed consent form should be signed and 
personally dated by [CONTACT_23522].  
11.[ADDRESS_741400] of consented subjects.  Eligible subjects, as determined by [CONTACT_564483] a treating investigator, will be registered on study at Cedars -Sinai Medical 
Center by [CONTACT_408].   
   
Issues that would cause treatment delays after registration should be discussed with the Principal 
Investigator (PI). If a patient does not receive protocol therapy following registration,  the patient’s 
registration on the study may be canceled.   
 
Subjects found to be ineligible will be recorded as screen failures.  Subjects found to be eligible will be 
registered . 
11.3.[ADDRESS_741401] undergo a  secondary eligibility verification by [CONTACT_564484] (CRO). The following documents will be completed and provided for review:  
 
 Applicable source documents  
 Eligibility checklist (signed by [CONTACT_1697])  
 Signed patient consent form a nd Subject’s Bill of Rights  
 HIPAA authorization form  
 
 
 
 
 
 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   36 
 11.3.2  Registration  
After eligibility is verified, registration is completed as follows:  
• Assign a patient study number  
• Enter the patient in OnCore  
 
Oversight by [CONTACT_458] [INVESTIGATOR_499413]  
11.4 Data Management and Monitoring/Auditing  
The data will be entered into a HIPAA -compliant database. The Study Staff will be responsible for data 
processing, in accordance with procedural documentation. Database lock  will occur once quality assurance 
procedures have been completed.  
 
All procedures for the handling and analysis of data will be conducted using good computing practices 
meeting FDA guidelines for the handling and analysis of data for clinical trials.  
11.5 Data  and Safety Monitoring  
11.5.1  Data Monitoring and Quality Assurance  
Adherence to the protocol, Good Clinical Practices (GCP), and institutional policy will be monitored by [CONTACT_1600] [INVESTIGATOR_499414] (DRG) meetings  or equivalent. 
In addition, the SOCCI CRO Quality Management Core (QMC) will conduct the following:  
 Audit preparations (AP) prior to audit conducted by [CONTACT_499439] (i.e. NCI or FDA). 
The purpose an AP is to ensure adequate source documen tation to support protocol compliance and 
data integrity are present and organized and to identify and correct any major findings prior to the 
external audit  
 A thorough review of selected subject cases, regulatory files, and IP accountability records (if 
applicable) within [ADDRESS_741402] is enrolled and annually thereafter while subjects 
are receiving investigational intervention.   
 Central eligibility verification for all subjects enrolled as described in protocol section 11.3.1.   
 Cent ral review of all eligibility waiver requests by a SOCCI Medical Reviewer to assess 
appropriateness and risk to ensure quality data and ensure subject safety protections for investigator -
initiated research  
 
For any protocol, QMC has the authority to reques t more frequent reviews or closer safety monitoring if it 
is deemed appropriate for any reason.  
11.5.[ADDRESS_741403]/study data. Adverse events and 
unanticipated problems are not expected, but if they occur they will be documented and reported according 
to CSMC IRB policies and procedures. If the PI [INVESTIGATOR_564448], enrollment may be held until the PI [INVESTIGATOR_292622] a modification to the study is necessary 
and/or the informed consen t documents are updated accordingly.  
 
In addition, this protocol will utilize oversight by a Safety Committee On Early Phase Studies (SCOEPS). 
Committee membership includes experts in the field of oncology and early phase studies and biostatistics. 
SCOEPS’ responsibilities are governed by [CONTACT_292665], or equivalent.   
 
The SCOEPS will provide routine monitoring of safety and enrollment for all early phase investigator -
initiated trials (IITs). The committee meets routinely and is responsible for reviewing and adjudicating all 
dose -limiting toxicities, dose escalations and appropriateness of the escalation, cohort exp ansion, subject 
replacements, select AEs, SAEs, and confirmation of attainment of maximum tolerated dose.  
 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   37 
 The SCOEPS findings and recommendations will be reported in writing to the Principal Investigator. A 
summary report will be forwarded by [CONTACT_39725] l Investigator or his/her designee to the Cedars -Sinai 
Medical Center IRB.  
11.[ADDRESS_741404] Retention  
 Study documentation includes all Case Report Forms, data correction forms or queries, source 
documents, monitoring/auditing logs/letters, and regulatory documents (e.g., protocol and amendments, 
IRB correspondence and approval, signed patient consent forms).  
 
 Source documents include all recordings of observations or notations of clinical activities and all 
reports and records necessary for the evaluation and recon struction of the clinical research study. 
Government agency regulations and directives require that the study investigator must retain all study 
documentation pertaining to the conduct of a clinical trial. Study documents should be kept on fi le per local 
guidelines.  
11.[ADDRESS_741405](s) to trial subjects without prior  IRB approval. For any such emergency modification implemented, 
the IRB must be notified as soon as possible, but no more than 10 days from the investigator’s awareness 
of the event.  
11.7.[ADDRESS_741406] or Others 
(UPI[INVESTIGATOR_9961]) Policy: Institutional Review Board/Research Compliance and Quality Impr ovement.  
 
A protocol exception most often involves a single subject and is not a permanent revision to the research 
protocol. Protocol exceptions that extend beyond a single subject should result in a protocol amendment to 
avoid serial violations.  
 
All exception requests must be reviewed by [CONTACT_564485]. The PI [INVESTIGATOR_292626]/his designee is responsible for submitting a protocol exception 
and its supporting documents to the SOCCI Medical  Director for review. Planned exceptions to the protocol 
that are more than logistical and/or have the potential to affect the subject’s safety and/or study integrity 
may not be implemented without prior approval from the SOCCI Medical Director and IRB.  
 
 Special considerations for Eligibility Waivers (EW)  
In general, subjects who do not meet the eligibility requirements should not be enrolled. In the rare event 
that it is appropriate for subject inclusion, the rationale/justification and subject case histo ry should be 
forwarded to the SOCCI CRO Medical Director for assessment prior  to submission to the IRB for approval.  
 
The CRO Medical Director will review the case and contact [CONTACT_564486] w arranted. The CRO Medical Director will provide a written 
assessment/recommended course of action. The CRO Medical Director’s assessment must be uploaded 
into Webridge with the waiver request for IRB review and consideration. The CRO Medical Director may 
recommend future protocol changes.  
 
 Eligibility Waiver Submission Process  
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   38 
 The PI [INVESTIGATOR_1238]/or treating physician should provide written request for waiver which includes case history and 
justification for prospective deviation from the study design to the SOCCI  CRO Medical Director.  
11.7.3  Other Protocol Deviations  
Logistical deviations from the protocol (e.g., minor changes to the study schedule for an individual subject) 
do not require prior IRB approval unless the deviation has the potential to affect the subject’s  safety. Such 
planned deviations that do meet this definition and do not affect the subject’s safety should be noted in the 
subject’s research record or deviation log as described in the SOCCI Clinical Research Office’s Working 
Instruction 11: Deviation an d Noncompliance Reporting.  
 
Unintentional deviations from the protocol that might affect subject safety or study integrity should be 
reported to the IRB within 10 days from when the investigator becomes aware that such a deviation has 
occurred, as outlined  in the SOCCI Clinical Research Office’s Working Instruction 11: Deviation and 
Noncompliance Reporting . In this case, a Protocol Deviation report must be submitted in Webridge,  per 
IRB policy, Reporting Possible Unanticipated Problems Involving Risks to Su bject or Others (UPI[INVESTIGATOR_9961]) 
Policy: Institutional Review Board/Research Compliance and Quality Improvement . All submissions should 
include a description of the plan to avoid similar deviations or exceptions in the future.   
11.7.[ADDRESS_741407] of the clinical trial at the site in accordance with 
Title 21 of the Code of Federal Regulations and/or the Declaration of Helsinki. The Principal Investigato r is 
responsible for personally overseeing the treatment of all study patients. The Principal Investigator [INVESTIGATOR_252949], including sub -investigators and other study staff members, adhere to 
the study protocol and all FDA/GCP/NC I regulations and guidelines regarding clinical trials both during and 
after study completion.  
 
The Principal Investigator [INVESTIGATOR_564449] R eport Forms. Periodically, monitoring visits will be conducted 
and the Principal Investigator [INVESTIGATOR_65448]/her original records to permit verification of proper 
entry of data. At the completion of the study, all case report forms will be revi ewed by [CONTACT_9532] [INVESTIGATOR_44302]/her final signature [CONTACT_10015].  
  
IIT201 6-16-POSADAS -TRC105  
Protocol Version [ADDRESS_741408] human leukemia -associated cell surface glycoprotein GP160 
defined by [CONTACT_28154]6.  Proc Natl Acad Sci U S A, 1986. 83(20): p. [ADDRESS_741409] a pre -B leukemic cell line.  J Immunol, 1988. 141(6): p. 1925 -33. 
3. Seon, B.K., et al., Long -lasting complete inhibition of human solid tumors in SCID mice by [CONTACT_564487].  Clin Cancer Res, 
1997. 3(7): p. 1031 -44. 
4. Li, D.Y., et al.,  Defective angiogenesis in mice lacking endoglin.  Science, 1999. 284(5419): p. 1534 -
7. 
5. Cheifetz, S., et al., Endoglin is a component of the transforming growth factor -beta receptor system 
in human endothelial cells.  J Biol Chem, 1992. 267(27): p. [ZIP_CODE] -30. 
6. Burrows, F.J., et al., Up-regulation of endoglin on vascular endothelial cells in human solid tumors: 
implications for diagnosis and therapy.  Clin Cancer Res, 1995. 1(12): p. 1623 -34. 
7. Seon, B.K., Expression of endoglin (CD105) in tumor blood vess els. Int J Cancer, 2002. 99(2): p. 
310-1; author reply 312.  
8. Horsman, M.R. and D.W. Siemann, Pathophysiologic effects of vascular -targeting agents and the 
implications for combination with conventional therapi[INVESTIGATOR_014].  Cancer Res, 2006. 66(24): p. [ADDRESS_741410] solid tumors by 
[CONTACT_28180] -endoglin monoclonal antibodies.  Clin Cancer 
Res, 1999. 5(2): p. 371 -82. 
10. Takahashi, N., et al., Antia ngiogenic therapy of established tumors in human skin/severe combined 
immunodeficiency mouse chimeras by [CONTACT_14181] -endoglin (CD105) monoclonal antibodies, and synergy 
between anti -endoglin antibody and cyclophosphamide.  Cancer Res, 2001. 61(21): p. 7846 -54. 
11. Tsujie, M., et al., Anti-tumor activity of an anti -endoglin monoclonal antibody is enhanced in 
immunocompetent mice.  Int J Cancer, 2008. 122(10): p. 2266 -73. 
12. Uneda, S., et al., Anti-endoglin monoclonal antibodies are effective for suppressing metastas is and 
the primary tumors by [CONTACT_28157].  Int J Cancer, 2009. 125(6): p. 1446 -53. 
13. Barbara, N.P., J.L. Wrana, and M. Letarte, Endoglin is an accessory protein that interacts with the 
signaling receptor complex of multiple members of the transforming growth factor -beta superfamily.  
J Biol Chem, 1999. 274(2): p. 584 -94. 
14. She, X., et al., Synergy between anti -endoglin (CD105) monoclonal antibodies and TGF -beta in 
suppression of growth of human endothelial cells.  Int J Cancer, 2004. 108(2): p. 251 -7. 
15. Guo, B., et al., CD105 inhibits transforming growth factor -beta-Smad3 signalling.  Anticancer Res, 
2004. 24(3a): p. 1337 -45. 
16. Warrington, K., et al., Functional role of CD105 in TGF -beta1 signalling in murine and human 
endothelial cells.  Anticancer Res, 2005. 25(3B): p. 1851 -64. 
17. Sanchez -Elsner, T., et al., Endoglin expression is regulated by [CONTACT_564488] -beta pathways.  J Biol Chem, 2002. 277(46): p. [ZIP_CODE] -
808. 
18. van La ake, L.W., et al., Endoglin has a crucial role in blood cell -mediated vascular repair.  
Circulation, 2006. 114(21): p. 2288 -97. 
19. Lenato, G.M. and G. Guanti, Hereditary Haemorrhagic Telangiectasia (HHT): genetic and 
molecular aspects.  Curr Pharm Des, 2006 . 12(10): p. 1173 -93. 
20. Sabba, C., et al., Life expectancy in patients with hereditary haemorrhagic telangiectasia.  QJM, 
2006. 99(5): p. 327 -34. 
21. Rokhlin, O.W., et al., Differential expression of endoglin on fetal and adult hematopoietic cells in 
huma n bone marrow.  J Immunol, 1995. 154(9): p. [ADDRESS_741411] carcinoma: vascular density determined using CD105 antibody correlates 
with tumor prognosis.  Cancer Res, 1999. 59(4): p. 856 -61. 
23. Vo, M.N., et al., Elevated plasma endogli n (CD105) predicts decreased response and survival in a 
metastatic breast cancer trial of hormone therapy.  Breast Cancer Res Treat, 2010. 119(3): p. 767 -
71. 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   40 
 24. Tanaka, F., et al., Evaluation of angiogenesis in non -small cell lung cancer: comparison betwee n 
anti-CD34 antibody and anti -CD105 antibody.  Clin Cancer Res, 2001. 7(11): p. 3410 -5. 
25. El-Gohary, Y.M., et al., Endoglin (CD105) and vascular endothelial growth factor as prognostic 
markers in prostatic adenocarcinoma.  Am J Clin Pathol, 2007. 127(4): p. [ADDRESS_741412] biochemical progression after 
radical prostatectomy.  Clin Cancer Res, 2008. 14(11): p. 3362 -6. 
27. Romani, A.A., et al., The risk of developi[INVESTIGATOR_564450]105 -positive vessel count.  J Surg Oncol, 2006. 93(6): p. 446 -55. 
28. Li, C., et al., Both high intratumoral microvessel density determined using CD105 antibody and 
elevated plasma levels of CD105 in colorectal cancer patients correl ate with poor prognosis.  Br J 
Cancer, 2003. 88(9): p. 1424 -31. 
29. Rubatt, J.M., et al., Independent prognostic relevance of microvessel density in advanced epi[INVESTIGATOR_564451]31, CD105, p53 status, and angiogenic marker 
expression: A Gynecologic Oncology Group study.  Gynecol Oncol, 2009. 112(3): p. 469 -74. 
30. Taskiran, C., et al., The prognostic value of endoglin (CD105) expression in ovarian carcinoma.  Int 
J Gynecol Cancer, 2006. 16(5): p. 1789 -93. 
31. Ding, S., et al., Comparative evaluation of microvessel density determined by [CONTACT_398]34 or CD105 in 
benign and malignant gastric lesions.  Hum Pathol, 2006. 37(7): p. 861 -6. 
32. Erdem, O., et al., CD105 expression is an independent predictor of survival in patients with 
endometri al cancer.  Gynecol Oncol, 2006. 103(3): p. 1007 -11. 
33. Yao, Y., et al., Prognostic significance of microvessel density determined by [CONTACT_2017] -
CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti -CD31 
monoclonal antibody.  Neuropa thology, 2005. 25(3): p. 201 -6. 
34. Yang, L.Y., et al., Correlation between CD105 expression and postoperative recurrence and 
metastasis of hepatocellular carcinoma.  BMC Cancer, 2006. 6: p. 110.  
35. Saad, R.S., et al., Endoglin (CD105) and vascular endothe lial growth factor as prognostic markers 
in esophageal adenocarcinoma.  Hum Pathol, 2005. 36(9): p. 955 -61. 
36. Kyzas, P.A., N.J. Agnantis, and D. Stefanou, Endoglin (CD105) as a prognostic factor in head and 
neck squamous cell carcinoma.  Virchows Arch, 200 6. 448(6): p. 768 -75. 
37. Marioni, G., et al., Endoglin expression is associated with poor oncologic outcome in oral and 
oropharyngeal carcinoma.  Acta Otolaryngol, 2006. 126(6): p. 633 -9. 
38. Bockhorn, M., et al., Differential vascular and transcriptional responses to anti -vascular endothelial 
growth factor antibody in orthotopic human pancreatic cancer xenografts.  Clin Cancer Res, 2003. 
9(11): p. 4221 -6. 
39. Davis, D.W., et al., Regional effects of an antivascular endothelial growth factor receptor 
monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B -V bladder cancer 
xenografts.  Cancer Res, 2004. 64(13): p. [ADDRESS_741413] N ew Drugs, 2014. 32(5): p. 851 -9. 
41. Shiozaki, K., et al., Antiangiogenic chimeric anti -endoglin (CD105) antibody: pharmacokinetics and 
immunogenicity in nonhuman primates and effects of doxorubicin.  Cancer Immunol Immunother, 
2006. 55(2): p. [ADDRESS_741414] -in-human study of TRC105 (Anti -Endoglin Antibody) in patients 
with advanced cancer.  Clin Cancer Res, 2012. 18(17): p. 4820 -9. 
43. Scher, H.I., et al., Trial Design and Objectives for Castration -Resistant Prostate Cancer:  Updated 
Recommendations From the Prostate Cancer Clinical Trials Working Group 3.  J Clin Oncol, 2016. 
34(12): p. 1402 -18. 
44. Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: revised RECIST 
guideline (version 1.1).  Eur J Cancer , 2009. 45(2): p. 228 -47. 
45. Scher, H.I., et al., Antitumour activity of MDV3100 in castration -resistant prostate cancer: a phase 
1-2 study.  Lancet, 2010. 375(9724): p. [ADDRESS_741415], G., et al., Selective inhibition of CYP17 with abiraterone acetat e is highly active in the 
treatment of castration -resistant prostate cancer.  J Clin Oncol, 2009. 27(23): p. 3742 -8. 
47. Azad, A.A., et al., Efficacy of enzalutamide following abiraterone acetate in chemotherapy -naive 
metastatic castration -resistant prostat e cancer patients.  Eur Urol, 2015. 67(1): p. 23 -9. 
IIT201 6-16-POSADAS -TRC105  
Protocol Version 1 dated 24AUG 2017   41 
 48. Noonan, K.L., et al., Clinical activity of abiraterone acetate in patients with metastatic castration -
resistant prostate cancer progressing after enzalutamide.  Ann Oncol, 2013. 24(7): p. 1802 -7. 
49. Johnson, V.E. and J.D. Cook, Bayesian design of single -arm phase II clinical trials with continuous 
monitoring.  Clin Trials, 2009. 6(3): p. 217 -26. 
50. Simon, R., Optimal two -stage designs for phase II clinical trials.  Control Clin Trials, 1989. 10(1): p. 
1-10. 
 
  
IIT201 6-16-POSADAS -TRC105  
Protocol Version [ADDRESS_741416] of CYP3A4 active agents (substrates & inhibitors)  
 
13.1 Appendix 1: Inhibitors of CYP3A4  
 
Amiodarone  
Anastrozole  
Azithromzcin  
Cannabinoids  
Cimetidine  
Clarithromycin  
Clotrimazole  
Cyclosporine  
Danazol  
Delavirdine  
Dexamethasone  
Diethyldithiocarbamate  
Diltiazem  
Dirithyromycin  
Disulfiram  
Entacapone (high dose)  
Erythromycin  
Ethinyl estradiol  
 Fluconazole  
Fluoxetine  
Fluvoaxamine  
Gestodene  
Grapefruit, Grapefruit juice  
Indinavir  
Isoniazid  
Ketoconazole  
Metronidazole  
Mibefradil  
Miconazole  
Nefazodone  
Nelfinavir  
Nevirapi[INVESTIGATOR_564452] (weak)  
Propoxyphene  
Quinidine  
Quinine  
Quinupristine and dalfopristin  
Ranitidine  
Ritonavir  
Saquinavir  
Sertindole  
Sertraline  
Troglitazone  
Troleandomycin  
Valproic acid  
 
 
13.2 Appendix 2: Inducers of CYP3A4  
Barbiturates  
Bosentan  
Carbamazepi[INVESTIGATOR_564453]. John’s wort  
Tipranavir/Ritonavir  
Troglitazone  
 
 
 
 
 
 